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ABSTRACT 
Addition of clonidine to local anaesthetic (LA) has been shown to increase its 
duration of action, but the mechanism by which it does this remains unclear.  Some 
authors have found that, at high concentrations, clonidine causes vasoconstriction and 
therefore LA remains at its site of action for longer.  Other research supports a 
pharmacodynamic mechanism of action of clonidine involving the cation current Ih. 
The aim of this study was to test whether adding clonidine to ropivacaine in 
transversus abdominis plane (TAP) blocks reduced plasma ropivacaine 
concentrations, indicating that clonidine causes vasoconstriction.  The secondary aim 
was to determine if adding clonidine to ropivacaine enhanced the action of 
ropivacaine by reducing abdominal wall sensation.  
In this double-blind randomized controlled trial, consenting patients having 
laparoscopic gynaecological surgery were allocated to receive TAP blocks with  
ropivacaine 3 mg/kg plain (control group), ropivacaine 3 mg/kg with 2 mcg/kg 
clonidine (clonidine group), ropivacaine 3 mg/kg with 1:400,000 adrenaline 
(adrenaline group), or ropivacaine 3 mg/kg plus a subcutaneous injection of 2 mcg/kg 
clonidine (SC clonidine group).  Total plasma ropivacaine levels were measured over 
six hours using gas chromatograph mass spectrometry.  Abdominal sensation 
(mechanical, heat, cold) was also measured.   
Eighty patients were recruited.  Groups were similar in terms of age, height, and ASA 
scores, but patients in the clonidine and SC clonidine groups had higher body weights 
than patients in the control group.  The plasma ropivacaine concentrations of the 
clonidine and SC clonidine groups were not different from those of the control group.  
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The ropivacaine concentrations of the adrenaline group were lower than the control 
group from 10 to 90 minutes after TAP block.  There were no consistent differences 
in abdominal wall sensation between groups. 
While it has been shown to cause vasoconstriction at higher concentrations (10-15 
mcg/ml), at a concentration of 1.35 mcg/ml clonidine does not cause vasoconstriction 
when added to ropivacaine.  The mechanism by which clonidine causes prolongation 
of LA action in the clinical setting is therefore likely to be pharmacodynamic. 
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CHAPTER 1:  INTRODUCTION 
Clonidine, when added to local anaesthetics in peripheral nerve blocks, improves the 
quality and increases the duration of anaesthesia and analgesia (Casati et al. 2001; 
Iohom et al. 2005; Iskandar et al. 2001).  This chapter begins with a review of local 
anaesthesia in general and the use of clonidine as an additive, followed by an 
appraisal of the evidence for and against the addition of clonidine to local anaesthetics 
in nerve blocks, and then concludes with a discussion of what is known about the 
possible mechanisms of action of clonidine added to local anaesthetics and the aims 
of the research described in this thesis. 
 
1.1  Historical perspective 
Coca has been used for thousands of years in parts of South America, including 
Bolivia, Ecuador, Venezuela, and Peru, but the first reliable account of its use was not 
recorded until 1539 (Calatayud & González 2003).  In 1653 Spanish Jesuit Bernabé 
Cobo first described the leaves’ analgesic effect in his manuscript on the New World 
(López-Valverde et al. 2011). 
And this happen’d to me once, that I repaired to a barber to have a tooth pull’d, that had work’d loose 
and ach’d, and the barber told me he would be sorry to pull it because it was sound and healthy; and a 
monk friend of mine who happen’d to be there and overhearing, advised me to chew for a few days on 
Coca. As I did, indeed, soon to find my toothache gone. 
Scientists first heard of the effects of chewing coca leaves from European explorers in 
the 19th century. The German chemist Albert Niemann was the first to isolate the 
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active component in 1860.  He named this cocaine (Calatayud & González 2003)  and 
rapid progress was then made towards introducing it as the first local anaesthetic.  
There were several reports on experiments that demonstrated the insensitivity 
produced when cocaine was used in animals. A Russian physician, Dr Basil Von 
Anrep, noted the local anaesthetic effect of cocaine when he injected it into himself.  
He was the first to suggest that cocaine anaesthesia could be useful for surgery 
(Calatayud & González 2003). 
The Viennese ophthalmologist Dr Carl Koller was the first to use cocaine clinically as 
a local anaesthetic in 1884, effectively anaesthetizing the mucosa of the eye with 
topical application (Koller 1884).  The news of this important discovery spread 
quickly across the Atlantic and piqued the interest of many, including the surgeons 
William Halsted and Richard Hall who experimented with cocaine immediately.  By 
the end of 1884, Hall reported the first known successful nerve block - an infraorbital 
plexus and inferior dental nerve block (Hall 1884).  Subsequently, Halstead and Hall 
performed clinical trials with cocaine as a regional anaesthetic in brachial plexus 
blocks and posterior tibial nerve blocks.  In 1885 they published their 
recommendations on the use of cocaine as a regional anaesthetic based on their 
observations in more than one thousand operations (Halstead 1885).  Unfortunately, 
both surgeons eventually became addicted to the substance and this had a significant 
impact on their lives and careers (López-Valverde et al. 2011). 
Regional anaesthesia continued to develop throughout the latter half of the 19th and 
20th centuries with the advent of newer local anaesthetic agents such as procaine in 
1905 and lignocaine in 1946 (Calatayud & González 2003).  Along with 
improvements in the efficacy and safety of local anaesthetic agents themselves during 
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this period, several drugs were also tested as additives to enhance the quality of nerve 
and plexus blocks.  In 1892 Alfredo Bignon described the addition of bicarbonate to 
cocaine to increase its potency.  He called this mixture “crème de cocaine” because it 
appeared milky due to the precipitation of cocaine crystals that occurred (Bignon 
1892).  The addition of adrenaline, now the most commonly used additive, was first 
described in 1905 by Heinrich Braun who used it in combination with novocaine 
(later named procaine).  Novocaine is a weak local anaesthetic so to prolong its 
duration of action high doses of adrenaline were added to cause local 
vasoconstriction, thus slowing the uptake that would otherwise limit its effect (Braun 
1905).  Braid and Scott realized the potential of using adrenaline as an additive both to 
prolong the duration of action of local anaesthetics as well as to reduce rapid systemic 
absorption and therefore the toxicity of local anaesthetic agents (Braid & Scott 1966).  
They investigated the effect of site of injection, local anaesthetic used, and the 
concentration of adrenaline on the pharmacokinetics of the local anaesthetics 
lignocaine and prilocaine.  They concluded that adrenaline had a greater effect on 
lignocaine and prilocaine when administered in tissues with increased vascularity and 
that an effect could be observed with concentrations of 1:80,000 and 1:200,000 
adrenaline.  In a later study, Scott et al concluded that 1:200,000 adrenaline was the 
optimal concentration to be used with local anaesthetics (Scott et al. 1972).  Although 
adrenaline remains the most commonly used vasoconstrictor in combination with 
local anaesthetics, other vasoconstrictors such as phenylephrine and felypressin are 
also efficacious in prolonging the local anaesthetic action (Leicht & Carlson 1986).       
The addition of vasoconstrictors and other agents to local anaesthetics continues in 
anaesthesia today.  Potential benefits conferred by an additive include more rapid 
speed of onset and prolongation of nerve blockade, improved quality of the block, 
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reduced systemic analgesic requirements, and reduced side effects of the local 
anaesthetic.  Adrenaline, phenylephrine, clonidine, dexmedetomidine, buprenorphine, 
dexamethasone, sodium bicarbonate, tramadol, ketamine, neostigmine and midazolam 
have all been added to local anaesthetics in nerve blocks with varying efficacy 
(Brummett & Williams 2011; Ansermino et al. 2003; Leicht & Carlson 1986).  While 
some of these agents have demonstrated efficacy in high quality clinical trials 
(Obayah et al. 2010; Esmaoglu et al. 2010; Candido et al. 2002; Parrington et al. 
2010), they are not without their attendant adverse effects.  Understanding about the 
mechanism of action of some of these agents in enhancing the effect of local 
anaesthetics is somewhat limited (Brummett & Williams 2011). 
The focus of the study described in this thesis is the use of clonidine as an additive to 
local anaesthetics in peripheral nerve blocks.  The remainder of this review will 
therefore address its efficacy and safety profile and discuss existing evidence for its 
potential mechanisms of action in this setting. 
 
1.2  Efficacy of clonidine as an additive in nerve blocks 
Clonidine was first used as a regional analgesic in 1984 by Tamsen and Gordh 
(Tamsen & Gordh 1984).  They injected clonidine into the epidural spaces of two 
patients with chronic pain and demonstrated that this produced analgesia.  
Subsequently, clonidine was trialed in the intrathecal space and used in addition with 
local anaesthetic drugs in peripheral nerve blocks.  Several randomized controlled 
trials (RCTs) (Eledjam et al. 1991; Casati et al. 2001; Iohom et al. 2005; Adnan et al. 
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2005) have been conducted into the efficacy of clonidine as an additive to local 
anaesthetics in nerve blocks but there are conflicting results. 
 
1.2.1  Regional nerve blocks  
Upper limb blocks 
Reports of fourteen RCTs (Eledjam et al. 1991; Gaumann et al. 1992; Singelyn et al. 
1992; Bernard & Macaire 1997; Erlacher et al. 2000; Saied et al. 2000; Erlacher et al. 
2001; Iskandar et al. 2001; Culebras et al. 2001; Casati et al. 2001; Iohom et al. 2005; 
Duma 2004; Adnan et al. 2005; Trifa et al. 2012) have been published in English on 
the use of clonidine as an additive to local anaesthetic in upper limb peripheral nerve 
blocks.  Nine of those studies (Eledjam et al. 1991; Singelyn et al. 1992; Bernard & 
Macaire 1997; Saied et al. 2000; Erlacher et al. 2001; Iskandar et al. 2001; Casati et 
al. 2001; Iohom et al. 2005; Adnan et al. 2005) demonstrated reduced pain, decreased 
analgesic requirement or prolonged sensory blockade with clonidine (ie were 
supportive of the use of clonidine) whereas five studies (Gaumann et al. 1992; 
Erlacher et al. 2000; Culebras et al. 2001; Duma 2004; Trifa et al. 2012) failed to 
demonstrate a benefit (ie were not supportive of the use of clonidine and were 
therefore negative studies) (table 1.1).
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Table 1.1. Randomised controlled trials of clonidine as an additive to local anaesthetic in upper limb peripheral nerve blocks 
Author P/G Block Type Clonidine Dose Local Anaesthetic Overall Outcome 
 
Eledjam, J J et al, 
1991 
 
60/2 
 
Supra-clavicular 
 
150 mcg 
 
1. B 0.25% 40-50 ml with cl 
2. B 0.25% 40-50 ml with adren 200 mcg 
 
Supportive 
Gaumann, D M et al, 
1992 
33/2 Axillary 50 mcg 1. L 1% 40 ml with cl  
2. L 1% 40 ml with adren 200 mcg 
Negative 
Singelyn, F J et al, 
1992 
30/3 Axillary 150 mcg 1. M 1% 40 ml with 1:200000 adren 
2. M 1% 40 ml with 1:200000 adren + SC cl  
3. M 1% 40 ml with 1:200000 adren and cl 
Supportive 
Bernard, J M and 
Macaire, P,         
1997 
56/4 Axillary 30, 90, 300 mcg 1. L 1% 40 ml with 5 ml saline 
2. L 1% 40 ml with 30 cl and saline 
3. L 1% 40 ml with 90 cl and saline 
4. L 1% 40 ml with 300 cl and saline 
Supportive 
Erlacher, W et al, 
2000 
40/2 Axillary 150 mcg 1. R 0.75% 40 ml with 1 ml saline 
2. R 0.75% 40 ml with cl 
Negative 
El Saied, A H et al, 
2000 
50/2 Axillary 150 mcg 1. R 0.75% 40 ml with 1 ml saline 
2. R 0.75% 40 ml with cl 
Supportive 
Erlacher, W et al, 
2001 
120/6 Axillary 150 mcg 1. M 1% 40 ml with 1 ml saline 
2. R 0.75% 40 ml with 1 ml saline 
3. B 0.5% 40 ml with 1 ml saline 
4. M 1% 40 ml with cl 
5. R 0.75% 40 ml with cl 
6. B 0.5% 40 ml with cl 
Supportive 
Iskandar, H et al, 
2001 
58/2 Mid-humeral 50 mcg 1. M 1.5% 40 ml 
2. M 1.5% 40 ml with cl 
Supportive 
Culebras, X et al, 
2001 
60/3 Interscalene 150 mcg 1. B 0.5% 40 ml with 1:200000 adren and 1 ml saline + 1 ml IM saline 
2. B 0.5% 40 ml with 1:200000 adren and 1 ml saline + IM cl 
3. B 0.5% 40 ml with 1:200000 adren and cl + 1 ml IM saline 
Negative 
Casati, A et al,    
2001 
30/2 Axillary 1 mcg/kg 1. R 0.75% 20 ml  
2. R 0.75% 20 ml with cl 
Supportive 
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Iohom, G et al,   
2005 
41/2 Axillary 100 mcg 1. M 1% 40 ml with 2 ml saline 
2. M 1% 40 ml with cl 
Supportive 
Duma, A et al,    
2005 
80/4 Axillary 150 mcg 1. LB 0.5% 40 ml with cl 
2. LB 0.5% 40 ml with 1 ml saline 
3. B 0.5% 40 ml with cl 
4. B 0.5% 40 ml with 1 ml saline 
Negative 
Adnan, T et al,   
2005 
28/2 Axillary 150 mcg 1. L 1% 40 ml with 1 ml saline 
2. L 1% 40 ml with cl 
Supportive 
Trifa, M et al,     
2012 
60/2 (paed) Axillary 1 mcg/kg 1. R 0.2% 0.4 mg/kg with 1ml saline 
2. R 0.2% 0.4 mg/kg with cl 
Negative 
 
Supportive studies include those that demonstrated reduced pain, decreased analgesic requirement or prolonged sensory blockade with clonidine and negative studies include those where no 
difference was observed with the addition of clonidine. 
Abbreviations: P/G, number of patients/groups; cl, clonidine; adren, adrenaline; SC, subcutaneous; IM, intramuscular; B, bupivacaine; L, lignocaine; M, mepivacaine; R, ropivacaine; LB, 
levobupivacaine
 8 
Two studies (Eledjam et al. 1991; Gaumann et al. 1992) compared the effects of the 
addition of either adrenaline or clonidine to brachial plexus blocks with conflicting 
results.  Eledjam et al performed 60 supraclavicular brachial blocks with 0.25% 
bupivacaine with the addition of either 200 mcg of adrenaline or 150 mcg of 
clonidine.  The authors found that bupivacaine and clonidine produced superior 
analgesia and prolonged duration of block (994 min with bupivacaine and clonidine 
compared with 728 min with bupivacaine and adrenaline; P<0.001) (Eledjam et al. 
1991).  However, Gaumann et al reported that clonidine was inferior to adrenaline as 
an additive (Gaumann et al. 1992).  In their study, 33 patients underwent axillary 
brachial plexus blocks with either 50 mcg of clonidine or 200 mcg of adrenaline 
added to 1% lignocaine. They found that patients reported higher pain scores in the 
clonidine group. These contradictory results may have resulted from the lower dose of 
50 mcg of clonidine used in this study compared with the 150 mcg used in the 
Eledjam study.  In the Gaumann study there was also a predominance of bone surgery 
in the clonidine group compared with soft tissue surgery in the adrenaline group.  It 
may be that the patients who had bone surgery were more likely to have higher pain 
levels post-operatively irrespective of whether they received clonidine or adrenaline. 
Singelyn et al (Singelyn et al. 1992) evaluated the efficacy of clonidine as well as its 
site of action (local or systemic) in a study using clonidine added to mepivacaine with 
adrenaline in 30 subjects who underwent axillary brachial plexus blocks.  The three 
groups studied received 1% mepivacaine plus 1:200,000 adrenaline alone (group A), 
mepivacaine and adrenaline plus 150 mcg subcutaneous (SC) clonidine (group B), or 
mepivacaine and adrenaline plus 150 mcg clonidine added to the local anaesthetic 
solution (group C).  The patients in group C had significantly increased duration of 
anaesthesia (prolonged by 32 and 37 min compared with groups A and B 
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respectively) and analgesia (prolonged by 89 to 103 min compared with groups A and 
B respectively) (P<0.0001).  The lack of difference between group A and group B in 
this study suggested that the prolongation of anaesthetic effect by clonidine was local 
rather than systemic.  However, Culebras et al found that clonidine did not prolong 
the duration of analgesia of brachial plexus blocks irrespective of the route of 
administration (Culebras et al. 2001).  They performed 60 interscalene brachial plexus 
blocks using 0.5% bupivacaine plus 1:200,000 adrenaline either alone, with 150 mcg 
intramuscular (IM) clonidine, or with 150 mcg clonidine in the block solution, and 
found no difference between duration of time to first analgesic request, pain scores or 
48 hour morphine consumption between the three groups.  The conflicting results of 
these two studies are difficult to interpret, and further studies are required to delineate 
the effect and site of action of clonidine added to local anaesthetic in upper limb nerve 
blocks. 
Bernard et al performed the only dose-finding study of clonidine in upper limb blocks 
available (Bernard & Macaire 1997).  They randomized 56 patients undergoing carpal 
tunnel surgery under axillary brachial plexus blocks to have 1% lignocaine with 0, 30, 
90, or 300 mcg of clonidine added.  Sensory and motor functions of the hand and 
forearm, adequacy of the block, post-operative pain levels (using both a visual 
analogue scale (VAS) and a verbal rating scale (VRS)), and adverse effects were 
assessed.  They reported that, compared with placebo, each dose of clonidine reduced 
the time to onset of neural blockade, reduced the need for additional local anaesthetic 
infiltration and intravenous sedation with midazolam, and produced a dose-dependent 
prolongation of analgesia (770 min with lignocaine with 300 mcg of clonidine 
compared with less than 200 min with lignocaine alone).  T
 10 
dose-dependent increase in adverse effects, particularly sedation and haemodynamic 
instability with the patients who received 300 mcg of clonidine.  
Iskandar et al designed a RCT with the aim of investigating the effect of clonidine on 
selective neural blockade in the forearm as well as determining whether it was 
mediated by a local or systemic mechanism (Iskandar et al. 2001).  Fifty-eight 
patients were randomized into two groups; Group 1 underwent a plain mepivacaine 
mid-humeral block of the median, musculocutaneous, ulnar, and radial nerves.  Group 
2 underwent a plain mepivacaine block of the ulnar and radial nerves and a 
mepivacaine plus 50 mcg clonidine block of the median and musculocutaneous 
nerves.  A blinded observer measured the time to onset and duration of sensory block 
using ice, and the motor function in the hand and forearm.  The authors measured 
thermoanaesthesia and motor function in these nerves rather than post-operative pain 
scores or analgesic use.  Thermoanaesthesia and motor blockade reflected the degree 
of block in the nerves of interest more accurately and were less likely to be affected 
by other factors.  The median and musculocutaneous nerves blocked with 
mepivacaine and clonidine had significantly prolonged sensory blockade of 
approximately 100 min compared with the mepivacaine-only group (median sensory 
block was 235 min and 240 min for the median and musculocutaneous nerves 
respectively in the clonidine group vs 150 min and 145 min respectively in the 
mepivacaine only group; P<0.0001).  The duration of the radial and ulnar nerve 
blocks did not differ between the two groups.  Therefore, the addition of clonidine to 
the median and musculocutaneous nerves of the patients in group 2 selectively 
prolonged the sensory block in these nerves without affecting the radial and ulnar 
nerves of the same arm.  The authors stated that this finding strongly supports a direct 
peripheral action of clonidine on the nerve because if clonidine acted via a central 
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mechanism then the clonidine added to the mepivacaine in group 2 would have 
caused a prolongation of anaesthesia in all four of the nerves.  
The only RCT of the use of clonidine in upper limb blocks in paediatric patients 
available was performed by Trifa et al (Trifa et al. 2012).  They conducted a double-
blind clinical trial that evaluated the effect of adding clonidine to brachial plexus 
blocks in children aged 1-6 years.  Sixty patients were randomized to receive a 
brachial plexus block with 0.4 ml/kg of ropivacaine 0.2% for forearm or hand surgery 
with or without 1 mcg/kg clonidine added to the local anaesthetic.  The patients’ pain 
levels were evaluated after operation using the Children’s Hospital of Eastern Ontario 
Pain Scale (CHEOPS), an observer based pain scale involving assessment of facial 
expression, verbal response, response to touching the wound, and torso or leg 
movement.  If pain scores were > 6, the patients received analgesia.  The post-
operative motor function was also recorded.  The authors found no significant 
difference between groups in terms of their observer-based pain assessments and the 
need for supplemental analgesia.  Although the time to first analgesic administration 
was 288 min in the placebo group and 437 min in the clonidine group, they concluded 
that the result was not statistically significant (P=0.06).  The authors performed a 
sample size calculation for this study based on a minimum effect size of 60% in the 
need for paracetamol in the postoperative period and determined that a minimum of 
29 patients per group was appropriate.  They did not perform a power calculation to 
determine the appropriate sample size to find a clinically significant difference in 
observer based pain assessments or difference in time to first analgesic administration.  
Therefore, the study may have been underpowered to detect a difference in these 
outcome measures. 
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Clonidine is used to increase the duration of single shot nerve blocks, but some 
research (Ilfeld et al. 2003; Ilfeld et al. 2005) has also focused on the role of clonidine 
in continuous upper limb nerve block infusions in improving post-operative analgesia.  
In a study by Ilfeld et al in 2003, 34 subjects undergoing upper limb orthopaedic 
procedures underwent infraclavicular brachial plexus blocks with 40 ml of 1.5% 
mepivacaine (with adrenaline 2.5 mcg/ml and bicarbonate 0.1 mEq/ml) (Ilfeld et al. 
2003).  A perineural catheter was placed for post-operative use and the patients 
received ropivacaine 0.2% either with or without clonidine 1 mcg/ml delivered by a 
portable infusion pump.  The infusion rate was 8 ml/hour and the patients were 
allowed patient-controlled boluses of 2 ml every 20 minutes.  The endpoints included 
post-operative pain scores, amount of bolus doses, oral analgesic use, sleep quality, 
and catheter and infusion-related complications.  The authors found that the addition 
of clonidine significantly decreased the number of patient-controlled 2 ml boluses on 
day 0 and day 1 after surgery (P<0.02).  However the overall difference in analgesic 
consumption was an average of 2-7 ml per day over the three day study period 
(P<0.02).  The dose of clonidine in this study may have been too low to produce a 
significant effect as there was no clonidine in the initial block solution.  Additionally, 
even with the 8 ml/hr infusion rate and maximum use of boluses, the patients would 
only receive 14 mcg of clonidine per hour.  It would have taken more than ten hours 
for the subjects to receive a total dose of 150 mcg of clonidine, the most common 
dose used in studies of single shot nerve blocks investigating clonidine as an additive 
(Eledjam et al. 1991; Singelyn et al. 1992; Erlacher et al. 2001; Saied et al. 2000; 
Erlacher et al. 2000; Culebras et al. 2001; Duma 2004; Adnan et al. 2005).  The 
catheter was placed blindly after the initial local anaesthetic solution was 
administered through the introducing needle.  The authors acknowledged that their 
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study was limited by the failure to confirm catheter placement.  The authors 
conducted a subsequent study in which they attempted to correct for these study 
design flaws (Ilfeld et al. 2005).  Twenty subjects underwent interscalene brachial 
plexus blocks in this study.  A stimulating catheter was used to place the catheter 
perineurally and then 40 ml of 1.5% mepivicaine with 2.5 mcg/ml adrenaline and 50 
mcg clonidine was injected through the catheter.  After surgery, the patients received 
an infusion of 0.2% ropivacaine with or without 2 mcg/ml clonidine via the catheter at 
a basal rate of 5 ml/hour with patient-controlled boluses of 5 ml and a lockout period 
of 1 hour.  The primary endpoint was “the most intense pain during the day after 
surgery” and the secondary endpoints were pain scores, patient-controlled bolus 
doses, oral analgesic use, sleep quality, and catheter- or infusion-related 
complications.  The authors did not find a statistically significant difference between 
groups in any of these endpoints.  This may be explained by an inadequate dosing of 
clonidine and a lack of power of the study. This study was designed to enroll 28 
patients, but only included 20 patients (10 per group) in the analysis because of the 
inability to place a perineural catheter in eight patients.  Ten patients in each group is 
not sufficient to detect differences in subjective measures such as pain scores and 
sleep quality.  It may not be sufficient to detect small but clinically relevant 
differences in patient-controlled bolus doses (especially with 1 hour lockout periods) 
and oral analgesic use. The clonidine given to both groups in the local anaesthetic 
solution before surgery may have been responsible for an undetected prolongation of 
the effect of local anaesthetic leading to a smaller outcome difference between the 
groups.   
Iskandar et al investigated the analgesic effect of clonidine alone when administered 
in an interscalene block for shoulder surgery (Iskandar et al. 2003).  They randomized 
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40 patients to an “interscalene group” (patients received 150 mcg clonidine in 15 ml 
of saline in an interscalene block and 1 ml saline subcutaneously) or a “systemic 
clonidine group” (patients received 15 ml of saline in an interscalene block and 150 
mcg clonidine subcutaneously).  The patients underwent general anaesthesia for their 
operations and post-operatively were given patient-controlled 8 ml perineural boluses 
of 0.2% ropivacaine with a lockout period of 1 hour.  The VAS measurements were 
significantly lower in the “interscalene group” in the recovery room (P<0.0001) but 
there were no significant differences in VAS results thereafter.  The duration of 
analgesia was increased and the consumption of ropivacaine was significantly reduced 
in the “interscalene group”.  Unfortunately, the magnitude of these effects in terms of 
the actual analgesic duration in the two groups and the quantities of ropivacaine 
consumed were not reported.  This study suggested that clonidine had a local 
analgesic effect.  
 
Lower limb blocks 
Six RCTs (Reinhart et al. 1996; Casati et al 2000; Couture et al. 2004; Mannion et al. 
2005; Helayel et al. 2005; Fournier et al. 2012) were published in English on the 
addition of clonidine to local anaesthetic in lower limb peripheral nerve blocks.   
When these studies are classified (see above) as simply being “supportive” of the use 
of clonidine in nerve blocks or “negative”, only two studies (Reinhart et al. 1996; 
Casati et al 2000) are supportive while four (Couture et al. 2004; Mannion et al. 2005; 
Helayel et al. 2005; Fournier et al. 2012) are negative (table 1.2). Interestingly, 
despite the relatively larger size of the nerves in the lower limb, the doses in the lower 
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limb studies were smaller than in the upper limb studies (Casati et al 2000; Couture et 
al. 2004; Mannion et al. 2005). 
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Table 1.2. Randomised controlled trials of clonidine as an additive to local anaesthetic in lower limb peripheral nerve blocks 
Author P/G Block Type Clonidine Dose Local Anaesthetic Overall Outcome 
 
Reinhart, D J et al, 
1996 
 
90/3 
 
Ankle/metatarsal 
 
75, 150 mcg 
 
1. L 2% 13 ml with 2 ml water 
2. L 2% 13 ml with 75 mcg cl 
3. L 2% 13 ml with 150 mcg cl 
 
Supportive 
Casati, A et al,    
2000 
60/3 Femoral/Sciatic 1 mcg/kg 1. R 0.75% 30 ml  
2. R 0.75% 30 ml with cl 
Supportive 
Couture, D J et al, 
2004 
64/2 Femoral/Sciatic 1 mcg/kg 1. B 0.5% 30 ml with 1:200000 adren 
2. B 0.5% 30 ml with 1:200000 adren and cl 
Negative 
Mannion, S et al, 
2005 
36/3 Psoas compartment 1 mcg/kg 1. LB 0.5% 0.4 ml/kg + IV saline 
2. LB 0.5% 0.4 ml/kg + IV cl 
3. LB 0.5% 0.4 ml/kg with cl  
Negative 
Helayel, P E et al, 
2005 
40/3 Sciatic 2 mcg/kg 1. R 0.5% 25 ml with placebo 
2. R 0.5% 25 ml + IM cl 
3. R 0.5% 25 ml with cl  
Negative 
Fournier, R et al, 
2012 
60/2 Sciatic 150 mcg 1. LB 0.5% 20 ml 
2. LB 0.5% 20 ml with cl 
Negative 
 
Supportive studies include those that demonstrated reduced pain, decreased analgesic requirement or prolonged sensory blockade with clonidine and negative studies include those where no 
difference was observed with the addition of clonidine. 
Abbreviations: P/G, number of patients/groups; cl, clonidine; adren, adrenaline; IV, intravenous; IM intramuscular; B, bupivacaine; L, lignocaine; R, ropivacaine; LB, levobupivacane
 17 
In 1996, Reinhart et al reported a dose-finding study of the addition of clonidine to 
local anaesthetic in ankle and metatarsal blocks (Reinhart et al. 1996).  Ninety 
patients undergoing bunionectomy or hammer toe repair surgery were randomized to 
receive ankle or metatarsal blocks with 15 ml of either plain 1.73% lignocaine, 1.73% 
lignocaine with 10 mcg/ml clonidine, or 1.73% lignocaine with 20 mcg/ml clonidine.  
The endpoints included the time of the onset and offset of block (measured by 
pinprick sensation), the onset of pain, the time to first analgesic request, the total 
analgesics required in the first 9 hours post-operatively, and post-operative pain 
assessed by VAS.  The authors reported no differences in pain scores and block onset 
and offset time.  However the patients in the group that received 10 mcg/ml clonidine 
had a significantly longer time to first reported pain (P<0.01), a longer time to first 
analgesic request (P<0.01), and a lower analgesic consumption (P<0.05).  There was 
no statistically significant difference between the lignocaine with 20 mcg/ml 
clonidine treatment group and the plain lignocaine group.  This may be because of an 
insufficient sample size as the 20 mcg/ml group had a high number of drop-outs (five 
patients).  
Casati et al and Couture et al investigated the effect of clonidine in combined 
femoral/sciatic nerve blocks, but reached different conclusions.  In the Casati study, 
30 patients undergoing hallux valgus repair were randomized to receive a block with 
30 ml of either plain 0.75% ropivacaine or 0.75% ropivacaine plus 1 mcg/kg 
clonidine (Casati et al 2000).  Couture evaluated 64 patients undergoing anterior 
cruciate ligament reconstruction and randomized them to receive a combined 
femoral/sciatic block with 30 ml of either 0.5% bupivacaine with 1:200,000 
adrenaline or 0.5% bupivacaine with 1:200,000 adrenaline and 1 mcg/kg clonidine 
(Couture et al. 2004).  Casati et al found that the group that received clonidine had a 
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delay in first analgesic request of three hours (from a mean of 13.7 hrs in the control 
group to 16.8 hrs in the clonidine group; P=0.038), but there was no difference in 
overall consumption of opioid analgesics post-operatively.  Couture et al found that 
clonidine conferred no significant advantages in terms of pain scores, duration of 
analgesia, or post-operative analgesic requirements.  Recently, Fournier et al 
conducted a RCT on 60 patients who received sciatic nerve blocks with 20 ml 
levobupivacaine 0.5% using a higher (150 mcg) clonidine dose in their treatment 
group (Fournier et al. 2012).  Despite the use of a higher dose of clonidine the authors 
did not detect a significant prolongation of analgesia in their clonidine group.  The 
time to first request for analgesia was 1215 min in the plain levobupivacaine group 
and 1275 min in the levobupivacaine with clonidine group and the difference was not 
statistically significant.  
Two RCTs (Mannion et al. 2005; Helayel et al. 2005) on regional anaesthesia of the 
lower limb included patient study groups that received systemic clonidine (IV or IM) 
with the aim of determining if the effect of clonidine was mediated by a local or 
systemic mechanism.  In the study by Mannion et al, 36 patients received psoas 
compartment blocks with 0.4 ml/kg of 0.5% levobupivacaine for hip fracture surgery.  
They were randomized to have either a plain levobupivacaine block, a 
levobupivacaine block plus 1 mcg/kg clonidine IV (systemic group), or a 
levobupivacaine block with 1 mcg/kg clonidine in the block (peripheral group) 
(Mannion et al. 2005).  In the 32 patients for whom the block was successful, there 
were no differences between groups in terms of pain scores or block onset, but it was 
found that 1 mcg/kg IV clonidine significantly prolonged the duration of block (from 
a mean of 7.3 hrs to 13.4 hrs; P=0.03).  The peripheral clonidine group also had a 
prolonged block with a mean of 10.3 hours but this was not statistically significant 
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when compared with the plain group of 7.3 hours (p>0.05).  This failure to detect a 
significant difference may have resulted from the small sample size of the study as the 
authors’ power calculation was designed to detect a four-hour difference in neural 
block duration and therefore only included 12 patients per group.   Furthermore, a 
dose of 1 mcg/kg of clonidine is relatively low and may be inadequate to increase the 
duration of the block.  Helayel et al recruited 40 patients undergoing foot or ankle 
procedures under combined femoral/sciatic nerve blocks (Helayel et al. 2005).  The 
blocks were performed using 25 ml of 0.5% ropivacaine either plain with 2 mcg/kg 
clonidine given IM, or with 2 mcg/kg clonidine added to the block solution.  No 
significant differences were found between groups in terms of onset time, quality of 
block, or block duration.   
Casati et al investigated the effect of clonidine in continuous lower limb nerve block 
infusions (Casati et al. 2005).  Sixty patients undergoing total knee arthroplasty 
received combined femoral/sciatic nerve blocks followed by femoral nerve patient-
controlled infusions.  In group 1 the patients received 25 ml of 0.75% ropivacaine for 
the femoral block and 0.2% ropivacaine in the femoral nerve infusion; in group 2 they 
received the above plus 1 mcg/kg clonidine with the 0.75% ropivacaine; and in group 
3 they received the above plus 1 mcg/kg clonidine with the 0.75% ropivacaine as well 
as 1 mcg/ml clonidine in the infusion.  The patient-controlled infusion was set at 6 
ml/hr with extra 2 ml boluses of the local anaesthetic mixture allowed up to every 20 
minutes.  All patients received “single shot” sciatic nerve blocks with 15 ml of 0.75% 
ropivacaine.  The authors found no significant differences between groups in terms of 
VAS measurements or total local anaesthetic consumption (170 vs 169 vs 164 ml on 
post-operative day one in groups 1, 2, and 3 respectively; P=0.51).  The clonidine 
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doses used would likely have been inadequate to improve the block of a large nerve 
like the femoral, possibly explaining the outcome. 
 
Other nerve and plexus blocks 
Seven RCTs (Molnar et al. 1997; Tschernko et al. 1998; Beaussier et al. 2005; 
Kaabachi et al. 2005; Danelli et al. 2006; Bollag et al. 2012; Naja et al. 2013) 
evaluated the effects of clonidine as an additive to non-limb nerve and plexus blocks 
(excluding eye blocks).  Four of the RCTs (Molnar et al. 1997; Beaussier et al. 2005; 
Kaabachi et al. 2005; Bollag et al. 2012) did not show any benefit with clonidine 
whereas three studies (Tschernko et al. 1998; Danelli et al. 2006; Naja et al. 2013) 
demonstrated benefit (table 1.3).   
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Table 1.3. Randomised controlled trials of clonidine as an additive to local anaesthetic in peripheral nerve blocks not involving the limbs 
Author P/G Block Type Clonidine Dose Local Anaesthetic Overall Outcome 
 
Molnar, R R et al, 
1997 
 
40/2 
 
Cervical plexus 
 
5 mcg/ml 
 
1. L 1.5% 7 mg/kg + 1:200000 adren 
2. L 1.5% 7 mg/kg + 5 mcg/ml cl 
 
Negative 
Tschernko, E M et al, 
1998 
36/3 Intercostal 2 mcg/kg 1. B 0.5% 2 mg/kg with saline + IM saline 
2. B 0.5% 2 mg/kg with saline + IM cl 
3. B 0.5% 2 mg/kg with cl + IM saline 
Supportive 
Beaussier, M et al, 
2005 
40/2 Ilioinguinal-
iliohypogastric 
75 mcg 1. R 0.75% 30 ml 
2. R 0.75% 30 ml with cl 
Negative 
Kaabachi, O et al, 
2005 
98/2 
(paed) 
Ilioinguinal-
iliohypogastric 
1 mcg/kg 1. B 0.25% 0.3 ml/kg 
2. B 0.25% 0.3 ml/kg with cl 
Negative 
Danelli, G et al,  
2006 
40/2 Cervical plexus 50 mcg 1. R 0.75% 20 ml 
2. R 0.75% 20 ml with cl 
Supportive 
Bollag, L et al,   
2012 
90/3 Transversus 
Abdominis Plane 
75 mcg 1. Saline 20.5 ml (each side) 
2. B 0.375% with 0.5 ml saline (each side) 
3. B 0.375% with cl (each side) 
Negative 
Naja, Z M et al,  
2013 
60/2 Paravertebral ~16 mcg at each 
paravertebral 
level for a       
70 kg patient 
1. 0.06 ml/kg at each paravertebral level of mixture containing: 2%       
     L, 2% L with adren, 0.5% B 
2. 0.06 ml/kg at each paravertebral level of mixture containing: 2%       
     L, 2% L with adren, 0.5% B + cl 
 
Supportive 
 
Supportive studies include those that demonstrated reduced pain, decreased analgesic requirement or prolonged sensory blockade with clonidine and negative studies include those where no 
difference was observed with the addition of clonidine. 
Abbreviations: P/G, number of patients/groups; cl, clonidine; adren, adrenaline; IM, intramuscular; bupivacaine; L, lignocaine; R, ropivacaine
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Molnar et al and Danelli et al investigated the effect of adding clonidine to cervical 
plexus blocks for carotid endarterectomy (Molnar et al. 1997; Danelli et al. 2006).  
Molnar et al randomized 40 patients to have combination superficial/deep cervical 
plexus blocks performed with 1.5% lignocaine (at a dose of 7 mg/kg) containing 
either 5 mcg/ml clonidine or 5 mcg/ml adrenaline (Molnar et al. 1997).  There was no 
difference in the onset time (8.4 vs 8.8 min) or the duration (139 vs 148 min) of 
neural blockade between groups.  The clonidine group experienced less tachycardia 
than the adrenaline group (P<0.003) and had higher serum lignocaine concentrations 
at all time points from 0 to 60 minutes (P<0.0002).  In Danelli’s study 40 patients 
received superficial cervical plexus blocks with 20 ml of 0.75% ropivacaine either 
alone or with 50 mcg clonidine (Danelli et al. 2006).  They found that clonidine 
significantly reduced the need for intraoperative local infiltration (8 vs 15 ml of 
lignocaine; P<0.05) and opioid supplements (0 vs 250 mcg of IV fentanyl; P<0.05).  
The mean duration of the block was 20 hrs in the clonidine group and 17 hrs in the 
non-clonidine group and this was not statistically significantly (P>0.05) (Danelli et al. 
2006). 
Two studies evaluating the effect of clonidine in ilioinguinal-iliohypogastric nerve 
blocks do not support the addition of clonidine to local anaesthetic (Beaussier et al. 
2005; Kaabachi et al. 2005).  Beaussier et al evaluated 40 adult patients undergoing 
inguinal hernia repair and randomized them to receive either 30 ml of 0.75% 
ropivacaine alone or with 75 mcg clonidine (Beaussier et al. 2005).  The patients’ 
post-operative pain levels were assessed on a VAS and time to first analgesic request 
recorded.  There were no differences in these parameters between groups.  The other 
ilioinguinal-iliohypogastric study was performed in children aged one to twelve years 
(Kaabachi et al. 2005).  Ninety-eight children undergoing inguinal hernia repair or 
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orchidopexy were randomized to receive blocks with 0.3 ml/kg of 0.25% bupivacaine 
with or without 1 mcg/kg clonidine.  Postoperatively, children below the age of six 
years were assessed using a modified CHEOPS, above the age of six using a VAS, 
and were provided with analgesia based on these scales.  The authors found no 
difference in post-operative analgesic use (percent of children who required analgesia 
during the first six days in the plain bupivacaine and clonidine groups were 30.6% 
and 20.4% respectively; P=0.17) and concluded that clonidine did not provide an 
advantage when added to local anaesthetic in ilioinguinal-iliohypogastric nerve 
blocks.  The study population was heterogeneous, age-wise, which is a limitation of 
this study.  Furthermore, the authors used two different assessments of post-operative 
pain to assess younger and older children.  
Tschernko et al evaluated the efficacy of clonidine in intercostal nerve blocks in 
patients undergoing thoractotomy (Tschernko et al. 1998).  Thirty-six patients were 
randomized to receive intercostal blocks with either 2 mg/kg of 0.5% bupivacaine 
plain, 2 mg/kg of 0.5% bupivacaine and 2 mcg/kg clonidine, or 2 mg/kg of 0.5% 
bupivacaine plus an IM injection of 2 mcg/kg clonidine (a systemic group).  The 
patients who received clonidine in the intercostal block had significantly lower VAS 
measurements, higher arterial oxygen tension, and lower analgesic consumption for 
the first four hours post-operatively.  This effect was not demonstrated in the patients 
who received systemically administered clonidine, suggesting that clonidine may 
have had a direct neural effect.  
There has only been one RCT investigating the effect of clonidine in Transversus 
Abdominis Plane (TAP) blocks (Bollag et al. 2012).  The investigators evaluated 90 
women undergoing TAP blocks after Caesarean section and randomized the women 
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to receive bilateral TAP blocks with 20.5ml of saline (placebo), with 0.375% 
bupivacaine, or with 0.375% bupivacaine with clonidine (75 mcg per side).  The aim 
of this study was to determine if clonidine decreased wound hyperalgesia (tested at 48 
hours) and chronic pain (assessed by telephone interview at three, six, and twelve 
months).  The authors found no significant difference in pain scores (VRS) or wound 
hyperalgesia between the three groups.  However, patients in the placebo group had 
significantly higher morphine consumption in the immediate post-operative period 
(17% of patients in the placebo group required morphine compared with 0% in the 
other two groups; P=0.01).  A criticism of this study was that the patients also 
received intrathecal morphine which would have provided analgesia over the same or 
longer time period as the TAP blocks. 
An RCT conducted by Naja et al demonstrated improved analgesic efficacy with 
clonidine in paravertebral blocks (Naja et al. 2013). Sixty patients received 
paravertebral blocks with a combination of lignocaine 2%, lignocaine 2% with 5 
mcg/ml adrenaline, 0.5% bupivacaine, and either saline or clonidine.  Compared with 
the patients who did not receive clonidine, the patients in the clonidine group 
consumed less tramadol at 48 hours, had lower pain scores from 24 to 72 hours post-
operatively at rest and associated with shoulder movement, and had a reduced time to 
resuming normal daily activity. 
Overall, there is evidence in the literature that the addition of clonidine to local 
anaesthetic prolongs the duration of action of the local anaesthetic.  This evidence is 
particularly strong in the case of upper limb nerve blocks.  There were significant 
study design flaws in several of the studies that were not supportive of the addition of 
clonidine to local anaesthetics.  These included:  small sample sizes; inadequate 
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dosing; and the use of surrogate markers such as pain scales or scores to assess 
duration of analgesia when a more direct evaluation of sensory block would be more 
appropriate to answer the research question of the study. 
 
1.2.2  Local anaesthetics used in peripheral nerve blocks  
The current literature supports the use of clonidine to prolong the duration of neural 
blockade when intermediate-acting local anaesthetics are used.  Numerous studies 
investigating the effect of clonidine on lignocaine and mepivacaine in nerve blocks 
have demonstrated its efficacy in prolonging the duration of local anaesthetic 
(Singelyn et al. 1992; Bernard & Macaire 1997; Erlacher et al. 2001; Iskandar et al. 
2001; Iohom et al. 2005; Adnan et al. 2005; Reinhart et al. 1996; Naja et al. 2013), 
whereas few studies have shown a lack of benefit (Gaumann et al. 1992; Molnar et al. 
1997).  However, when long-acting local anaesthetics were used, the results were 
more heterogeneous.  Erlacher et al investigated the efficacy of clonidine with 
different local anaesthetics by adding clonidine to brachial plexus blocks containing 
mepivacaine, ropivacaine, or bupivacaine (Erlacher et al. 2001). They recruited 120 
trauma patients and randomized them to receive one of six blocks: 40 ml of 1% 
mepivacaine with or without 150 mcg clonidine, 40 ml of 0.75% ropivacaine with or 
without 150 mcg clonidine, and 40 ml of 0.5% bupivacaine with or without 150 mcg 
clonidine.  Motor activity was assessed on a six point modified Lovett rating scale.  
Sensory block was defined as the time from the administration of the brachial plexus 
block to the first report of post-operative pain.  The authors reported that clonidine 
prolonged the duration of block in the bupivacaine and mepivacaine but not the 
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ropivacaine groups.  However, they did not specify whether this referred to motor or 
sensory block or both, and also failed to provide P-values for these results.  
In 2007, McCartney et al published a qualitative systematic review of the efficacy of 
the addition of clonidine to local anaesthetics in peripheral nerve blocks.  They 
reported that the evidence for its efficacy when added to long-acting local 
anaesthetics was inconclusive (McCartney et al. 2007).  They included several 
supportive as well as negative studies for the addition of clonidine to ropivacaine and 
bupivacaine and also highlighted that two studies failed to show a benefit of adding 
clonidine to levobupivacaine (Mannion et al. 2005; Fournier et al. 2012).  However 
two years later Pöpping et al published a meta-analysis that showed that there was no 
evidence of any difference between clonidine’s effect on intermediate and long-acting 
local anaesthetics (Pöpping et al. 2009).  
The intrinsic vasoactivity of the local anaesthetic used in a peripheral nerve block 
may impact the effect of an added vasoconstrictor (including clonidine if it acts by 
vasoconstriction).  The vasodilatation caused by some local anaesthetics (prilocaine, 
bupivacaine, levobupivacaine) is attenuated by vasoconstrictors (Wienzek et al. 2007; 
Newton 2005; Iida et al. 1997) which may prolong their duration of action.  However, 
some local anaesthetics such as ropivacaine have instrinsic vasoconstrictor action 
(Wienzek et al. 2007; Timponi et al. 2006; Iida et al. 1997), and the effect of adding a 
vasoconstrictor to these local anaesthetics is less clear. 
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1.2.3  Dose of clonidine used in peripheral nerve blocks 
The doses of clonidine used in peripheral nerve blockade in the literature vary widely 
from 30 to 300 mcg.  The most common doses are 150 mcg or 2 mcg/kg body weight.  
Three studies investigated the dose-response relationship of clonidine in peripheral 
nerve blocks with varying results (Bernard & Macaire 1997; Singelyn et al. 1996; 
Reinhart et al. 1996).  Bernard et al, in their axillary nerve block study detailed above, 
did not find a dose-response relationship in terms of onset of sensory block or 
sedation, but they reported a dose-dependent prolongation of analgesia and a 
reduction in VAS and VNRS between the 300 mcg and 30 mcg clonidine groups at 
260 minutes after the block. Dose-dependent haemodynamic instability was also 
observed, however.  Three patients in the 300 mcg group had a mean arterial pressure 
less than 55 mmHg and consequently two patients could not be discharged as 
planned.  In the study by Singelyn et al 80 patients underwent axillary brachial plexus 
blocks for hand surgery (Singelyn et al. 1996).  The local anaesthetic solutions used 
consisted of 40 ml of 1% mepivacaine with 1:200,000 adrenaline and either saline 
(control group) or one of seven doses of clonidine: 0.1, 0.2, 0.3, 0.4, 0.5, 1, and 1.5 
mcg/kg.  The time to onset of thermoanaesthesia was measured using ethanol-soaked 
swabs and the patients were also taught to measure offset of thermoanaesthesia in this 
manner, which they then recorded in the post-operative period after discharge.  The 
time to offset of analgesia was measured as the time to onset of pain.  The onset times 
and analgesic requirements were similar among groups.  The minimum doses of 
clonidine required to prolong anaesthesia and analgesia significantly were 0.5 mcg/kg 
and 0.1 mcg/kg respectively.  In contrast, Reinhart et al, in their study described 
above, failed to show any evidence of dose-responsiveness with clonidine (Reinhart et 
al. 1996). The group that received 150 mcg clonidine had significantly lower VNRS 
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three hours after the block (P<0.05), as well as a significantly longer time to onset of 
pain (P<0.01) and time to first analgesic request (P<0.01).  However the group that 
received 300 mcg clonidine experienced no statistically significant improvement over 
plain lignocaine in terms of time to the onset of pain or time to the first analgesic 
request.  The authors acknowledged that their study was underpowered for the 
outcome measures used.  
In a meta-analysis by Pöpping et al there was no evidence for a dose-response 
relationship of clonidine in peripheral nerve or plexus blocks in terms of benefit or 
harm (Pöpping et al. 2009).  Twenty RCTs in which patients underwent peripheral 
nerve blocks as a sole surgical anaesthetic were included.  The doses of clonidine 
used in the studies varied from 90 to 150 mcg of clonidine.  There was no dose-
response relationship in terms of time to block onset, duration of motor or sensory 
block, duration of analgesia, or adverse effects.  The authors suggested that it may not 
have been possible to identify a dose-response relationship from these studies because 
most of the trials used the same dose of clonidine (150 mcg). 
  
1.3  Adverse effects of clonidine as an additive in nerve blocks  
The adverse effects of clonidine are centrally mediated, occurring when clonidine is 
absorbed into the systemic circulation, resulting in a reduction in sympathetic outflow 
and sedation (Stoelting & Hillier 2012). 
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1.3.1  Haemodynamic effects of clonidine 
Clonidine, through its central sympatholytic effect, causes a reduction in heart rate 
and blood pressure when administered systemically (Stoelting & Hillier 2012), and 
when used with local anaesthetic in a peripheral nerve block may cause hypotension 
and bradycardia. 
In an early dose-finding study by Bernard and Macaire where clonidine in doses of 
30, 90, and 300 mcg were used in brachial plexus blocks, significant decreases in 
arterial blood pressure were observed with 300 mcg doses, leading the authors to 
conclude that the adverse events were dose-dependent (Bernard & Macaire 1997).  
They therefore recommended the use of 30-90 mcg of clonidine for brachial plexus 
blocks.  In their systematic review, McCartney et al also reported the haemodynamic 
effects of clonidine to be dose-dependent based on their analysis of nine studies in 
which there was an increase in adverse events in the clonidine groups (McCartney et 
al. 2007).  
Pöpping et al meta-analysed the results of RCTs in which patients received local 
anaesthetic nerve blocks (with and without clonidine) as the sole anaesthetic for 
surgery (Pöpping et al. 2009).  Seven RCTs examined the incidence of arterial 
hypotension and bradycardia using various specific definitions (hypotension: 
“decrease in mean arterial pressure less than 55 mmHg, decrease in systolic blood 
pressure more than 20% or 30%, need for ephedrine”; bradycardia: “heart rate less 
than 45 beats/min or less than 50 beats/min, more than 20% decrease in heart rate, 
need for atropine”).  The incidence of arterial hypotension in the patients who did not 
receive clonidine was 4.1% compared with 13.1% in the patients who received 
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clonidine (OR 3.61; 95% CI 1.52-8.55).  The incidence of bradycardia in the patients 
who did not receive clonidine was 4.1% compared with 8.5% in the patients who 
received clonidine (OR 3.09; 95% CI 1.10-8.64). 
Numerous studies have been conducted using 150 mcg or 2 mcg/kg of clonidine 
added to local anaesthetic and have shown no difference in the incidence of adverse 
effects (Singelyn et al. 1992; Eledjam et al. 1991; Erlacher et al. 2001; Saied et al. 
2000; Ilfeld et al. 2005; Duma 2004).  Most clinicians therefore limit the dose of 
clonidine to 150 mcg. 
 
1.3.2  Sedation 
Although clonidine causes sedation when administered intravenously this occurs less 
frequently when added to local anaesthetics in peripheral nerve blocks.  McCartney et 
al reviewed 27 studies and reported that only five of those studies reported an increase 
in sedation in the patients who received clonidine as an additive (McCartney et al. 
2007).  Of the patients in these studies who became sedated, only one experienced 
oxygen desaturation to below 90% and that patient was given 300 mcg of clonidine.  
No patients required ventilatory support.  
The meta-analysis by Pöpping et al included four RCTs that reported at least one 
episode of sedation (Pöpping et al. 2009).  The RCTs used different four- and five-
point rating scales to measure sedation (Antonucci 2001; Beaussier et al. 2005; 
Bernard & Macaire 1997; Casati et al. 2001).  In studies where sedation was reported, 
55.8% of patients who received clonidine experienced at least one episode of sedation 
compared with 32.4% of patients who did not receive clonidine (OR 2.28%, P=0.04).  
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There was no dose-dependent relationship for sedation demonstrated with clonidine 
and doses ranged from 30 to 300 mcg.  
 
1.4  Proposed mechanisms of action of clonidine in nerve blocks 
Clonidine is a selective partial agonist at the alpha-2 adrenergic receptor with 
approximately 220:1 selectivity for the alpha-2 over the alpha-1 receptor (Stoelting & 
Hillier 2012).  The precise mechanism by which clonidine prolongs the duration of 
local anaesthetic action in peripheral nerve blocks remains unclear.  It is unknown 
whether the effect is centrally or peripherally mediated, and if it is peripherally 
mediated, whether the effect is pharmacodynamic or pharmacokinetic in nature.  
 
1.4.1  Central vs peripheral mechanisms 
Animal studies have been performed to elucidate whether the effect of clonidine on 
local anaesthetic duration is centrally or peripherally mediated (Buerkle et al. 1999; 
Dogrul & Uzbay 2004).  Buerkle et al utilized a rat inflamed knee joint model in 
which pain was induced by injecting kaolin and carrageenan into the right knee joint.  
Some animals received saline into the right knee and acted as a control group.  Rats 
were randomized to receive clonidine either via an intrathecal or intra-articular 
catheter at the start of the experiment.  The rats that had intrathecal clonidine were 
further divided into groups receiving intrathecal yohimbine (an alpha-2 antagonist) or 
not.  Rats that received intra-articular clonidine were further divided into groups to 
which either intra-articular or subcutaneous yohimbine was administered.  Baseline 
tests of thermal and mechanical nociception (thermal withdrawal response to heat 
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stimulus and mechanical withdrawal response to von Frey filaments) were performed 
before the inflammation was induced. Nociception was then re-assessed over 240 
minutes.  The investigators found that both intrathecal and intra-articular clonidine 
produced anti-nociceptive effects.  In the rats that received intrathecal yohimbine, the 
anti-nociceptive effect of clonidine was decreased.  Intra-articular yohimbine also 
decreased the anti-nociceptive effect of intra-articular clonidine and this inhibition 
was greater than that observed when subcutaneous yohimbine was administered.  This 
indicated that clonidine was acting at the knee joint itself rather than centrally.  Were 
clonidine acting via a central mechanism to produce anti-nociception then yohimbine 
should have been equally or more effective when given subcutaneously. 
Dogrul and Uzbay investigated the effect of clonidine on the tails of mice and 
demonstrated that the anti-nociceptive action of clonidine is peripherally mediated via 
alpha-2 adrenoceptors (Dogrul & Uzbay 2004).  In this study the tails of the mice 
were immersed in clonidine solution at concentrations of 20, 50, or 75 mg/ml after 
baseline nociception was measured.  Nociception was assessed using the radiant heat 
tail-flick test.  A concentration-dependent anti-nociception was observed with 
clonidine compared with the baseline nociception of the mice tails.  The anti-
nociception did not extend to the proximal areas of the tail that were not exposed to 
the clonidine solution.  This suggested that the anti-nociceptive effect was locally 
mediated.  When systemic yohimbine was administered to the mice prior to tail 
immersion, the anti-nociceptive effect of clonidine was inhibited, indicating that the 
effect was alpha-2 adrenoceptor mediated.  
Numerous clinical studies investigating the effect of clonidine in peripheral nerve 
blocks allocated some patients to receive systemic clonidine (intravenous, 
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intramuscular, or subcutaneous) and other patients to receive clonidine in their nerve 
blocks in order to determine if the mode of action of clonidine was peripheral or 
central (Singelyn et al. 1992; Culebras et al. 2001; Mannion et al. 2005; Helayel et al. 
2005; Tschernko et al. 1998; Iskandar et al. 2003; Barioni et al 2002; YaDeau et al. 
2008).  The majority of these studies indicated that the site of action was peripheral ie 
clonidine acts locally at the nerves (Singelyn et al. 1992; YaDeau et al. 2008; Barioni 
et al 2002; Iskandar et al. 2003; Tschernko et al. 1998).  In their 1992 study already 
described above, Singelyn et al found that clonidine produced significantly longer 
duration of analgesia and anaesthesia when added to the local anaesthetic compared 
with the plain local and systemically administered clonidine groups (P<0.0001), 
which supported a peripheral mechanism of action.  Tschernko et al found similar 
results in their RCT, also previously described, involving patients who received 
intercostal nerve blocks for thoracotomy (Tschernko et al. 1998). Patients for whom 
clonidine was added to the block had lower VAS, lower analgesic requirements, and 
higher arterial oxygen tension for the first four hours (P<0.05).  The systemic 
clonidine group was not different from the controls, supporting the notion that 
clonidine did not act centrally. 
Iskandar et al and YaDeau et al also reported that the mechanism of action of 
clonidine was peripheral rather than central (Iskandar et al. 2003; YaDeau et al. 
2008).  In their study already described above, Iskandar et al found that clonidine 
administered via an interscalene catheter improved analgesia compared with the 
group given the agent subcutaneously, concluding this suggested a direct peripheral 
action of clonidine.   YaDeau et al reported similar results from a trial involving 99 
patients undergoing popliteal fossa nerve blocks for foot or ankle surgery (YaDeau et 
al. 2008).  The patients received popliteal fossa nerve blocks with 30 ml of 
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bupivacaine 0.375% and were randomized to receive either no clonidine (control 
group), 100 mcg of clonidine intramuscularly (IM) (systemic group), or 100 mcg of 
clonidine with the bupivacaine in the nerve block (block group).   The patients also 
underwent a combined spinal-epidural anaesthetic and a saphenous nerve block.  The 
authors reported a longer duration of analgesia (time from block administration to 
first reported pain) in the block group (18 ± 6 hours) compared with the control group 
(15 ± 7 hours) (P=0.016) and the systemic group (14 ± 7 hours).  They concluded that 
clonidine administered peripherally with the local anaesthetic in popliteal nerve 
blocks, but not systemically, was effective in increasing the duration of neural 
blockade. 
Clonidine is also used in ophthalmic blocks to decrease the time to the onset and 
increase the duration of neural blockade.  Barioni et al, in a study on 60 patients who 
received peribulbar blocks, investigated the effect of oral versus locally administered 
clonidine (Barioni et al 2002).  The patients were randomized to a control group (oral 
saline and peribulbar saline), a clonidine eye group (oral saline and 30 mcg peribulbar 
clonidine), a clonidine oral group (150 mcg oral clonidine and peribulbar saline), and 
a clonidine eye and oral group (150 mcg oral clonidine and 30 mcg peribulbar 
clonidine).  They found that the patients in the “clonidine eye group” and the patients 
in the “clonidine eye and oral group” had a longer time to the first analgesic request 
(1111 ± 544 min and 1052 ± 578 min respectively) compared with the control group 
(625 ± 534 min) (P=0.0158 and P=0.0287 respectively).  The “clonidine oral group” 
did not experience any prolongation in the duration of analgesia, which again 
supported a local effect of clonidine. 
 35 
The study described previously by Iskandar et al in 2001 on clonidine in midhumeral 
blocks supported a peripheral site of action of clonidine in nerve blocks (Iskandar et 
al. 2001).  Pratap et al conducted a similar type of study where participants acted as 
their own controls (Pratap et al. 2007).  Twenty volunteers received subcutaneous 
infiltration of lignocaine in one arm and lignocaine with clonidine in the contralateral 
arm.  The median time for the return of normal sensation was greater than 6 hours in 
the volunteers when clonidine was added to the lignocaine compared with 3.5 hours 
when lignocaine alone was infiltrated (P<0.001).  This provided further evidence that 
clonidine exerted its effects by a peripheral mechanism.  
Conversely, Bharti et al and Mannion et al suggested that, when administered in nerve 
blocks, clonidine is absorbed into the systemic circulation where it exerts its effects 
centrally (Bharti et al. 2013; Mannion et al. 2005).  Bharti et al evaluated 60 patients 
undergoing open cholecystectomy and showed lower pain scores and analgesic 
consumption in patients who had received clonidine either intravenously or with local 
anaesthetic in wound infiltration compared with local anaesthetic alone (Bharti et al. 
2013).  There were no observed differences in intravenous versus local clonidine and 
this may be explained by the fact that the sample size was too small (approximately 
19 per group) to compare surrogate pain markers such as pain scores and analgesic 
use.  The study described earlier by Mannion et al involving psoas compartment 
blocks for hip surgery demonstrated an effect with systemic (intravenous) clonidine 
but no peripheral effect, supporting a central site of action (Mannion et al. 2005). 
Overall, the current literature supports predominantly a peripheral site of action of 
clonidine.  This was most clearly demonstrated by the studies of Iskandar and Pratap 
(Iskandar et al. 2001; Pratap et al. 2007).  Although it is possible that clonidine, when 
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used in combination with local anaesthetics in nerve blocks, could be absorbed into 
the systemic circulation and cause analgesic effects centrally, it is unlikely that this is 
the main mechanism for the prolongation of local anaesthetic effect observed with 
clonidine.  Burlacu et al measured the plasma concentrations of clonidine after 
combined levobupivacaine 0.25% and clonidine 150 mcg paravertebral blocks and 
showed that significant absorption of clonidine into the systemic circulation occurred 
(Burlacu et al. 2007).  However, the plasma clonidine concentrations were less than 
the previously described effective levels after IV administration, leading the authors 
to conclude that the effect of clonidine could not be entirely centrally-mediated and a 
peripheral mechanism must be at least partly responsible. 
 
1.4.2  Central mechanisms 
When considering possible central mechanisms of action for clonidine, the literature 
supports predominantly a spinal effect site.  Alpha-2 receptors are present in the 
dorsal horn of the spinal cord and clonidine may act both pre- and post-synaptically to 
produce analgesia and anaesthesia (Chan et al. 2010).  Cavillo and Ghignone 
demonstrated that clonidine decreased the excitability of primary afferent terminals in 
the dorsal root ganglion of cats (Calvillo & Ghignone 1986).  They also showed that 
this effect is likely alpha-2 mediated and was reversed by yohimbine or phentolamine.  
A second possible mechanism of clonidine acting pre-synaptically in the dorsal root 
ganglion was reported by Ono et al (Ono et al. 1991).  They used rat spinal cord slices 
and exposed them to various alpha agonists and antagonists.  They demonstrated that 
clonidine decreased substance P release and that this decrease was attenuated by pre-
treatment of the spinal cord slices with yohimbine and with piperoxane, both alpha-2 
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antagonists.  They concluded that clonidine caused decreased substance P release by 
acting at alpha-2 receptors. At the post-synaptic level clonidine causes 
hyperpolarisation and reduced spontaneous activity in neurons of the dorsal horn 
(Chan et al. 2010). 
The high density of alpha-2 adrenoceptors in the locus coeruleus may be responsible 
for some of the hypnotic or sedative effects of alpha-2 agonists (Correa-Sales et al. 
1992).  These receptors are probably not, however, involved in anti-nociception 
because the direct administration of alpha-2 agonists to the brainstem does not 
produce analgesia (Khan et al. 1999).  The role of these supra-spinal alpha-2 receptors 
in anti-nociception remains unclear.  There is good evidence that the anti-nociceptive 
effect of clonidine is predominantly mediated in the spinal cord (Chan et al. 2010; 
Khan et al. 1999).   
 
1.4.3  Peripheral mechanisms 
Pharmacokinetic mechanisms 
It has been postulated that at least part of the local anaesthetic prolongation effect of 
clonidine is due to vasoconstriction (Mazoit et al. 1996; Kopacz & Bernards 2001).  
Although clonidine is generally thought of as a selective alpha-2 adrenoceptor 
agonist, it also has some activity at alpha-1 adrenoceptors, with a selectivity ratio of 
220:1 (Stoelting & Hillier 2012).  One hypothesis is that the local activation of alpha-
1 adrenoceptors causes vasoconstriction and hence decreased washout of local 
anaesthetic from its site of action, a mechanism of action similar to that of adrenaline 
when added to local anaesthetics.  However, it is also possible that clonidine causes 
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vasoconstriction by another mechanism as alpha-2 agonists have previously been 
shown to stimulate post-junctional vascular smooth muscle receptors resulting in 
vasoconstriction (Flacke 1992). 
Kopacz and Bernards attempted to address this pharmacokinetic hypothesis in their 
study conducted on seven human volunteers (Kopacz & Bernards 2001).  They 
inserted microdialysis probes adjacent to the participants’ superficial peroneal nerves 
bilaterally and then injected 1% lignocaine along one nerve and 1% lignocaine with 
10 mcg/ml clonidine along the contralateral nerve.  They then measured the 
extracellular lignocaine concentration and assessed cutaneous blood flow using 
Doppler ultrasound, finding that clonidine increased the duration of sensory block 
(P<0.01) and the cutaneous blood flow was decreased in the clonidine group 
(P=0.01).  The tissue lignocaine concentration was plotted against time, and the area 
under the curve (AUC) and mean residence time (MRT) were significantly greater in 
the lignocaine with clonidine group compared to the plain lignocaine group (AUC: 
22,824 vs 16,678 mcgyminyml-1, P<0.05; MRT: 74 vs 48 min, P<0.05).  This 
supported the hypothesis that some of the effect of clonidine on local anaesthetic 
action is pharmacokinetic.  
Mazoit et al conducted a randomized controlled trial with 24 patients undergoing 
general or orthopaedic surgery with epidural anaesthesia (Mazoit et al. 1996).  These 
patients received epidural solutions containing: 1) 20 ml of 2% lignocaine and 2 ml of 
saline; 2) 20 ml of 2% lignocaine with 1:200,000 adrenaline and 2 ml of saline; 3) 20 
ml of 2% lignocaine and 300 mcg of clonidine (equivalent to a concentration of 15 
mcg/ml of clonidine); or 4) 20 ml of 2% lignocaine with 1:200,000 adrenaline and 
300 mcg of clonidine.  The plasma lignocaine concentrations of these patients were 
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measured over time, and the investigators found that the plasma concentration of 
lignocaine and, in particular, the maximum observed concentration (Cmax), was 
similar in the clonidine and adrenaline groups.  Furthermore, both of these two groups 
had much lower Cmax values compared with the plain lignocaine group.  The authors 
concluded that clonidine produced a similar degree of vasoconstriction to adrenaline. 
A clinical study published in the dental literature also found clonidine to be 
comparable to adrenaline in terms of its vasoconstrictor properties (P. M. Patil & S. P. 
Patil 2012).  In this study, 50 patients undergoing third molar extraction were 
randomized to receive an intraoral block with either 2% lignocaine with clonidine or 
2% lignocaine with adrenaline.  The weight of blood-soaked gauze used for the 
procedure and the time to stable clot formation as determined by the surgeon were 
used to indicate the vasoconstriction associated with the two drugs.  No significant 
differences were found between the groups in terms of vasoconstrictor properties, and 
the authors concluded that clonidine could provide an alternative to using adrenaline 
in blocks particularly in hypertensive patients. 
In 1992, however, Gaumann conducted a study involving 33 patients who were 
randomized to receive brachial plexus blocks with 40 ml of either a 1% lignocaine 
with adrenaline (200 mcg) or 1% lignocaine with clonidine (150 mcg; a clonidine 
concentration of 3.75 mcg/ml) (Gaumann et al. 1992).  Venous blood samples were 
obtained from 29 of these patients and the plasma lignocaine concentrations were 
measured using fluorescence polarization immunoassay.  The authors found that 
plasma lignocaine concentrations were higher and occurred earlier in the clonidine 
group and concluded that clonidine did not have vasoconstrictor activity.  However, 
due to the lack of a control group receiving lignocaine alone, the only conclusion that 
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can be drawn from their results is that clonidine has less vasoconstrictor activity than 
adrenaline.   
 
Pharmacodynamic mechanisms 
There is increasing evidence that the analgesic action of clonidine in peripheral nerve 
blocks is mediated by pharmacodynamic mechanisms (Kroin et al. 2004; Dalle et al. 
2014; Butterworth & Strichartz 1993; Yilmaz-Rastoder et al. 2012).  In 1993, 
Butterworth and Strichartz, using a sucrose gap technique, demonstrated that 
clonidine and the more specific alpha-2 agonist, guanfacine, inhibited compound 
action potentials in rat sciatic nerve fibers (Butterworth & Strichartz 1993).  Both 
agents inhibited both tonic and phasic impulse conduction in a concentration-
dependent manner, preferentially inhibiting the C fibers to a greater extent than the A-
alpha fibers.  This study supported the hypothesis that clonidine had a peripheral 
effect mediated by the alpha-2 receptor.  The concentrations of clonidine the 
investigators used, however, were significantly higher than the clinical concentrations 
to which a nerve is usually exposed after a block has been performed.  In 2012, 
Yilmaz-Rastoder et al performed similar experiments on rat sciatic nerves, evaluating 
the effect of clinical concentrations of buprenorphine, clonidine, dexamethasone, and 
midazolam on compound action potentials (Yilmaz-Rastoder et al. 2012).  They found 
that at 1 mcg/ml of clonidine [estimated to be a clinically relevant concentration based 
on inferences from Ilfeld’s studies using clonidine with ropivacaine infusions (Ilfeld 
et al. 2005; Ilfeld et al. 2003)] there was a small (less than 50% of maximal) but 
significant reduction of the amplitude of C fibre action potentials (P=0.045).  
 41 
Clonidine acts as a partial agonist at alpha-2 adrenoceptors where it is known to 
produce most of its effects.  However, there is evidence that suggests that its effect on 
peripheral nerves is not alpha-2 mediated (Kosugi et al. 2010; Leem et al. 2000; Kroin 
et al. 2004).  Leem et al performed experiments on rat sciatic nerves and showed that 
both clonidine and yohimbine produced a reduction in the compound action potential 
amplitude (Leem et al. 2000).  When clonidine and yohimbine were applied to the 
sciatic nerve together, the action potential amplitude was reduced to a similar degree 
as the mean of the amplitude reduction produced by each of the two agents when used 
independently.  This suggested that yohimbine did not antagonise the effect of 
clonidine.  They also found that idazoxan (a more selective alpha-2 antagonist) did 
not inhibit the clonidine-induced amplitude reduction.  The authors concluded that the 
effect of clonidine on peripheral nerve fibers was not alpha-2 mediated.   Kosugi et al 
investigated the effects of clonidine and dexmedetomidine (a more selective alpha-2 
agonist) on the compound action potential of frog sciatic nerves (Kosugi et al. 2010).  
They demonstrated that dexmedetomidine and clonidine reduced the amplitude of 
compound action potentials with doses that were much greater than used clinically.  
When examining the effect of yohimbine on clonidine and dexmedetomidine, they 
showed that yohimbine did not reduce the inhibition of the action potential.  They 
concluded from this that the neural effects of clonidine and dexmedetomidine are not 
alpha-2 mediated.  The investigators also examined the effect of alpha-1 agonists such 
as adrenaline, noradrenaline, and phenylephrine on the action potential.  They 
demonstrated that these agents had no effect on the inhibition of the action potential 
by clonidine and dexmedetomidine and concluded that alpha-1 activity was unlikely 
to be involved in the prolongation of local anaesthetic effect by alpha-2 agonists. 
However, the studies using the rat inflamed knee joint model by Buerkle et al 
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supported a role of alpha-2 receptors in the anti-nociceptive action of clonidine 
(Buerkle et al. 1999).  They clearly found that yohimbine given at the site of clonidine 
delivery (intra-articular) inhibited its anti-nociceptive effects. 
There exists strong evidence that some of the prolongation effect of clonidine in 
peripheral nerve blocks is mediated by its action on the hyperpolarization-activated 
cation current (Ih) (Parkis & Berger 1997; Dalle et al. 2014; Kroin et al. 2004).  The 
HCN channel that mediates the Ih is a highly selective voltage-gated cation channel 
found in neurons and cardiac pacemaker cells as well as other cell types.  When the 
HCN channel is activated by hyperpolarization, there is an influx of Na+ and K+ ions.  
This results in a slow inward current and returns the membrane potential towards its 
resting potential, preventing excessive hyperpolarization after an action potential 
(Pape 1996).  In 1997, Parkis and Berger investigated the effect of clonidine on the Ih 
in rat hypoglossal motoneurons (Parkis & Berger 1997).  The study, using 
intracellular recording techniques as well as alpha receptor agonists and antagonists, 
demonstrated that clonidine reduced Ih in hypoglossal neurons at rest, resulting in a 
reduction in resting membrane potential.  Clonidine reduced Ih by decreasing the 
voltage activation threshold of Ih to more hyperpolarized potentials as well as 
reducing the maximum amplitude of the Ih (Ihmax) and slowing the time course of 
activation of Ih.  Yohimbine and idazoxan (both alpha-2 antagonists) reduced the 
effects of clonidine on the Ih voltage activation and the activation time course of the 
current, demonstrating that at least some of clonidine’s effects are alpha-2 mediated.  
This mechanism was further supported when guanabenz (an alpha-2 agonist) also 
caused hyperpolarization and increased the peak input resistance in hypoglossal 
motoneurons.  However, it is likely that not all of the analgesic effects of clonidine 
are alpha-2 mediated because the antagonists (yohimbine and idazoxan) did not alter 
 43 
the reduction in Ih maximum amplitude nor the slowing of Ih activation when the 
nerves were in their most hyperpolarized state.  Parkis and Berger hypothesized that 
these effects that were not altered by alpha-2 antagonists may in fact be secondary to 
a physical block by clonidine of the HCN channels.  
Yagi and Sumino investigated the effect of clonidine on Ih using rat dorsal root 
ganglion (DRG) neurons (Yagi & Sumino 1998).  They used whole cell voltage 
clamp recording techniques, and showed that clonidine inhibited Ih in DRG neurons 
and the percentage inhibition ranged from 35 to 43%.  In 2001, Dalle et al reported 
the effect of clonidine on the C fibers of the rabbit vagus nerve (Dalle et al. 2014).  
They used the sucrose-gap method and showed that when clonidine was applied to the 
C fibers, there was an increase in the hyperpolarization after stimulation.  A similar 
enhancement of hyperpolarization occurred when ZD 7288 (an HCN channel blocker) 
or Ba2+ (a blocker of the inwardly rectifying potassium current IKIR) were applied to 
the C fibers.  When ZD 7288 and clonidine were applied together no additive effect of 
the two agents was observed indicating that they were acting on the same channel.  
When Ba2+ and clonidine were applied together, the hyperpolarization was greater 
than when either of the two agents were applied alone.  This suggested that the two 
agents were acting at different channels.  Overall, this study demonstrated that 
clonidine inhibited Ih.  
Kroin et al investigated the effect of prolongation of local anaesthetic action by 
clonidine in vivo in their animal studies on rats (Kroin et al. 2004).  They performed 
sciatic notch injections containing 1% lignocaine either alone or in combination with 
one or more of: clonidine, adrenaline, ZD 7288, forskolin or 8-Br-cAMP (the latter 
two being drugs that enhance Ih).  The duration of sensory block was measured by 
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pinprick foot withdrawal.  They found that when prazocin or yohimbine was 
administered into the sciatic notch prior to lignocaine and clonidine there was no 
attenuation of the block prolongation observed with clonidine and concluded that 
clonidine’s effect is not alpha-mediated.  They showed that ZD 7288 prolonged the 
local anaesthetic effect to a similar degree as clonidine and that in combination with 
clonidine, no additive effect of ZD 7288 was observed.  When forskolin or 8-Br-
cAMP (Ih enhancers) was used in combination with clonidine, the prolongation of 
sensory block observed with clonidine alone was reduced.  These findings supported 
the previous studies that showed that clonidine inhibited Ih.  
 
1.5  Rationale of study 
Clonidine has been shown to increase the duration of local anaesthetic action when 
used in combination with local anaesthetic for regional anaesthesia.  However the 
mechanism by which this occurs remains unclear.  Using autonomically denervated 
dogs, Flacke described the effect of alpha-2 adrenergic agonists as directly 
stimulating post-junctional vascular smooth muscle receptors resulting in 
vasoconstriction (Flacke 1992).  In human subjects, Mazoit et al demonstrated a 
vasoconstrictor effect of clonidine when given with a local anaesthetic in the epidural 
space (Mazoit et al. 1996).  The study by Kopacz and Bernards reported a slower 
lignocaine washout occurred when clonidine was added to local anaesthetic for 
superficial peroneal nerve blocks (Kopacz & Bernards 2001).  These studies 
supported a pharmacokinetic mechanism of action of clonidine.  However, there is 
also evidence that the clonidine added to local anaesthetic prolongs nerve blockade 
and this is mediated by pharmacodynamic mechanisms (Parkis & Berger 1997; Yagi 
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& Sumino 1998; Kroin et al. 2004).  This study was undertaken to assess the role, if 
any, of a pharmacokinetic vasoconstrictor mechanism by which clonidine prolongs 
the action of local anaesthetic.   
If clonidine does cause vasoconstriction when added to local anaesthetic then lower 
plasma ropivacaine concentrations would be observed which would reduce the risk of 
local anaesthetic toxicity.  Local anaesthetic toxicity has been demonstrated to occur 
when the total venous plasma ropivacaine concentration is approximately 2.2 mcg/ml 
based on the study by Knudsen et al (Knudsen et al. 1997).  The authors studied the 
central nervous and cardiovascular effects of intravenous ropivacaine infusions on 12 
healthy volunteers and found that the mean maximum tolerated arterial plasma 
concentration of ropivacaine (defined as the total arterial plasma concentration at 
which subjects developed signs and/or symptoms of local anaesthetic toxicity) was 
4.3 mcg/ml.  Venous blood was also sampled at this time point and the mean total 
plasma ropivacaine concentration was found to be 2.2 mcg/ml.   
 
1.6  Hypotheses 
The null hypothesis of this study was that clonidine does not cause vasoconstriction.  
To test this, plasma ropivacaine concentrations were measured following transversus 
abdominis plane (TAP) blocks performed with solutions of either plain ropivacaine, 
ropivacaine with clonidine, ropivacaine with adrenaline, or plain ropivacaine plus 
subcutaneous clonidine.   
The secondary aim of the study was to measure the effect of adding clonidine to TAP 
blocks in terms of abdominal wall sensation to cold, warmth, and mechanical stimuli 
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at three and six hours after administration of the block.  The null hypothesis was that 
adding clonidine to the local anaesthetic solution would have no effect on these 
sensory modalities. 
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CHAPTER 2:  RESEARCH METHODOLOGY 
Approval of the study protocol and all amendments was obtained from the Sydney 
Local Health District Ethics Review Committee (RPAH zone) [ethics approval 
number X14-0011 & HREC/14/RPAH/10]. 
 
2.1  Study design 
This was a randomised, double-blinded, parallel-group, single centre study conducted 
at Royal Prince Alfred Hospital, Sydney, Australia.  After obtaining written informed 
consent on the day of surgery, 80 patients undergoing laparoscopic gynaecological 
surgery were randomized into four groups.  Subjects underwent anaesthetic according 
to a standardised anaesthetic protocol and received ultrasound-guided transversus 
abdominis plane (TAP) blocks.  In Group I patients received TAP blocks with 0.2% 
ropivacaine (control group); Group II patients 0.2% ropivacaine with 1:400,000 
adrenaline (adrenaline group); Group III patients 0.2% ropivacaine and clonidine 2 
mcg/kg (clonidine group); and Group IV patients 0.2% ropivacaine and subcutaneous 
(SC) clonidine 2 mcg/kg (SC clonidine group).  The plasma ropivacaine 
concentrations were measured, and mechanical, heat, and cold sensation was assessed 
at three and six hours after administration of the block.   
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2.2  Study population and recruitment 
The subjects were recruited into the study on the day of surgery in The Perioperative 
Unit at the Royal Prince Alfred Hospital.  The eligible participants were women aged 
between 18 and 65 years who were undergoing laparoscopic gynaecological surgery 
for which a TAP block would be a component of their pain management and who did 
not meet any of the exclusion criteria below.  The study protocol was fully explained 
to each subject and an Information for Participants brochure (Appendix I) was 
provided.  Subjects gave their written informed consent to participate (Appendix II: 
Participant Consent Form). 
The exclusion criteria included: 
• Patients who declined written consent 
• Known allergy to ropivacaine, adrenaline, or clonidine 
• Morbidly obese patients (Body Mass Index or BMI > 40) 
• Evidence of infection at the site of TAP block placement 
• Pre-existing neurological or muscular disease, coagulopathy, significant renal 
or liver disease 
• Pregnancy 
 
2.3  Randomization and blinding 
The subjects were assigned to one of four TAP block groups using a web-based 
randomisation tool (https://www.randomizer.org).  The anaesthetist in charge 
prepared the “block” solutions for each subject and had no further involvement in the 
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study.  The subjects and the investigator were blinded to the group allocations.  The 
anaesthetist in charge was not blinded to the study group so that an additional element 
of safety was provided should an adverse event or medical emergency arise. 
 
2.4  Study protocol 
2.4.1 Baseline data collection 
The following data were documented about each subject pre-operatively: age, height, 
weight, American Society of Anesthesiologists (ASA) physical status score, and co-
morbidities.  The surgical procedure for each subject was also recorded. 
 
2.4.2  Anaesthesia and analgesia protocol 
No premedication was administered to the subjects.  In the anaesthetic room an 18-
gauge cannula was placed into a vein in the arm of the subject.  Once inside the 
operating theatre, standard monitoring (pulse oximetry, electrocardiography, and 
automated non-invasive blood pressure) was established.  Anaesthesia was induced 
with propofol 2 mg/kg and fentanyl 1.5 mcg/kg.  Endotracheal intubation was 
facilitated with rocuronium 0.6 mg/kg.  Anaesthesia was maintained with sevoflurane.  
The subjects received a further 1.5 mcg/kg of fentanyl during the procedure.  All 
subjects also received paracetamol 1g, parecoxib 40 mg, and ondansetron 4 mg unless 
contraindicated.  Hypotension defined as systolic blood pressure <30% of baseline 
was treated with metaraminol in 0.5 mg boluses, and bradycardia (heart rate <45) with 
atropine in 300 mcg boluses.  On completion of surgery, residual neuromuscular 
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blockade was reversed with sugammadex 200 mg and subjects were extubated when 
awake.   
In the post-anaesthetic care unit, post-operative analgesia was standardised with 
intravenous fentanyl boluses of 20 mcg administered to the subjects as needed up to 
200 mcg.  When oral analgesia was tolerated, the patients were provided with regular 
oral paracetamol 1 g every 6 hours and oral oxycodone 5-10 mg every 2 hours as 
required up to a maximum of 12 doses in 24 hours.  If this was insufficient, 
subcutaneous morphine 5-7.5 mg every 3 hours as required up to a maximum of 8 
doses in 24 hours was administered. 
The subjects received anti-emetic medications as required according to a post-
operative nausea and vomiting protocol that included ondansetron 4-8 mg, 
prochlorperazine 6.25-12.5mg, and droperidol 0.5 mg. 
 
2.4.3  Study interventions   
After anaesthesia was induced, ultrasound-guided bilateral posterior TAP blocks were 
performed.  The same investigator performed all the TAP blocks.  Each subject 
received a block with 0.2% ropivacaine, the volume of which was adjusted for the 
weight of the subject.   
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Each subject received one of four solutions for their TAP block: 
1. Ropivacaine 3 mg/kg plain (control group) 
2. Ropivacaine 3 mg/kg with 2 mcg/kg clonidine (clonidine group) 
3. Ropivacaine 3 mg/kg with 1:400,000 adrenaline (adrenaline group) 
4. Ropivacaine 3 mg/kg plus a subcutaneous injection of 2 mcg/kg clonidine (SC 
clonidine group) 
This dosing schedule was chosen because a large volume of anaesthetic is clinically 
appropriate for a TAP block.  Additionally, similar doses were used in a previous 
study by Loadsman et al(Loadsman et al. 2013) which demonstrated a significant 
difference between the Cmax and Tmax of the plain ropivacaine and ropivacaine with 
adrenaline groups and therefore it was thought that this would provide a good 
comparison group if any vasoconstriction was observed with the addition of clonidine 
to ropivacaine.  The clonidine dose was selected because 2 mcg/kg of clonidine was 
used in other similar studies.(Helayel et al. 2005; Tschernko et al. 1998) 
All the TAP blocks were performed using a SonoSite M-Turbo ultrasound machine 
with a linear probe (SonoSite Australasia, Brookvale, NSW).  The ultrasound probe 
was placed on the anterolateral abdominal wall and then translocated postero-laterally 
to rest in the mid-axillary line superior to the iliac crest (figure 2.1) (Hebbard et al. 
2007). 
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Figure 2.1. Ultrasound guided TAP block showing anatomical landmarks.  (Permission to use image 
granted by NYSORA). (NYSORA 2013)   
After skin disinfection with an alcohol swab (Kendall Webcol Alcohol Prep) at the 
site of injection, a SonoPlex® cannula (Pajunk, Geisingen, Germany) was inserted 
through the skin medial to the ultrasound probe.  An in-plane approach was used to 
guide the needle through the subcutaneous fat, external oblique muscle, and the 
internal oblique muscle to the transversus abdominis plane which lies between the 
internal oblique and the transversus abdominis muscles, (figure 2.2).  After a negative 
aspiration of blood, 2 ml of the block solution was injected to confirm correct needle 
tip location by hydrodissection, following which the remaining solution was injected.  
The TAP block was then performed on the contralateral side. 
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Figure 2.2.  Muscle layers of the abdominal wall as seen with ultrasound and simulated needle insertion and 
spread of local anaesthetic (blue shaded area).  The external oblique muscle (EOM), internal oblique muscle 
(IOM), and transversus abdominis muscle (TAM) are shown.  (Permission to use image granted by 
NYSORA) (NYSORA 2013)  
 
2.5 Study outcomes 
2.5.1  Plasma ropivacaine concentration 
The primary study outcome was to determine if the addition of clonidine to 
ropivacaine in TAP blocks caused local vasoconstriction thereby limiting the washout 
of ropivacaine from the TAP plane.   The plasma ropivacaine concentrations were 
measured at 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, and 360 minutes.  If clonidine 
caused local vasoconstriction, it was expected that the plasma ropivacaine 
concentrations in the clonidine group would be lower than those of the control group; 
and/or the peak plasma concentration of ropivacaine would be lower and occur later 
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in the clonidine group.  Adrenaline is a known vasoconstrictor and therefore an 
adrenaline group was included in the study to enable comparison of the degree of 
vasoconstriction (if any) that occurred with clonidine compared with that associated 
with adrenaline.  The subcutaneous (SC) clonidine group was included to enable a 
comparison of the effect of clonidine on plasma ropivacaine concentrations when 
administered systemically compared with clonidine administered with the TAP block 
injectate. 
After induction of anaesthesia a cannula was inserted into the external jugular vein of 
the subjects to facilitate blood sampling for the measurement of plasma ropivacaine 
concentrations.  Subsequently, blood samples (5 ml) were obtained at predetermined 
time intervals (10, 20, 30, 40, 50, 60, 90, 120, 150, 180, and 360 minutes) after the 
initiation of the TAP block. 
The blood samples were transported to the Department of Anaesthetics Laboratory for 
analysis of plasma ropivacaine concentration.  They were centrifuged at 4000 rpm at 
4°C for 15 minutes to separate the plasma from the other blood components.  Using a 
pipette, the plasma was then removed from the sample and transferred to labeled 
polypropylene tubes.  The samples were then stored in the freezer at -80°C until 
processing, usually one week later (see 2.6 below for laboratory methods). 
 
2.5.2  Abdominal wall sensation 
Baseline (normal) warm, cold, and mechanical sensation of the abdominal wall of 
subjects was confirmed by performing baseline sensory tests prior to anaesthesia in 
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the anaesthetic room.  The sensation of the abdominal wall to warm, cold, and 
mechanical stimuli was then tested at three and six hours after the TAP block.   
The warm sensation was tested using small heated pouches (Pocket Hand Warmer, 
Kathmandu®, Melbourne, Australia), measuring 12 by 7 cm and weighing 96 grams.  
Each polyvinyl chloride pouch contained 12% distilled water, 88% sodium acetate, 
and a small flexible metal disc.  When the disc inside was bent, the temperature of the 
pouch increased rapidly to 55°C and remained at this temperature for approximately 
one hour.  These pouches were placed sequentially on each dermatome of the 
abdominal wall from T8 to L1 approximately 5 cm left of the midline and the subject 
was asked to indicate whether or not they sensed the pack as warm at each position.  
The right side of the abdominal wall was then tested in a similar way.    
The cold sensation was tested using alcohol swabs (Kendall Webcol® Alcohol Prep – 
saturated with 70% isopropyl alcohol, Minneapolis, USA) in a similar manner.  Each 
dermatome from T8 to L1 on the left side of the abdominal wall was tested and the 
subject was asked to indicate whether or not they sensed the swab as cold at each 
position.  Thereafter, the right side of the abdominal wall was tested. 
The mechanical cutaneous sensation was assessed and mechanical detection threshold 
(MDT) established in each dermatome bilaterally using Von-Frey Hairs (DanMic 
Aesthesio®, Precise Tactile Sensory Evaluator 20 piece Kit, Campbell, USA) (figure 
2.3).  The Von-Frey Hair kit consists of 20 nylon monofilaments of varying lengths 
and diameters that when applied perpendicularly to the skin to the point where the 
monofilament bends 3-5mm, a specific amount of force is delivered (figure 2.4) 
(Keizer 2009).  The range of force that could be achieved with the Von-Frey Hair Kit 
was 0.008 grams to 300 grams.  However the force was converted to a linear 
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logarithmic scale, log10 (10 x F) or log of 10 times the force F in milligrams, as 
described by Voerman et al (Voerman et al. 2000).  The filaments are imprinted with 
both the target force in grams as well as the monofilament size in the logarithmic 
scale (table 2.1). 
 
 
Figure 2.3.  Danmic Aesthesio Sensory Evaluators (Permission to use image granted by Linton 
Instrumentation) (Linton Instrumentation 2011) 
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Figure 2.4.  Von-Frey Hair used to evaluate tactile cutaneous sensation (Permission to use image granted by 
Linton Instrumentation) (Linton Instrumentation 2011)  
Table 2.1. Von-Frey monofilaments size and target force (Permission to use table granted by Linton 
Instrumentation) (Linton Instrumentation 2011) 
Monofilament Target 
Size Force (Grams)  
1.65 .008 
2.36 .02 
2.44 .04 
2.83 .07 
3.22 .16 
3.61 .40 
3.84 .60 
4.08 1.0 
4.17 1.4 
4.31 2.0 
4.56 4.0 
4.74 6.0 
4.93 8.0 
5.07 10 
5.18 15 
5.46 26 
5.88 60 
6.10 100 
6.45 180 
6.65 300 
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The first assessment of MDT was performed in the anaesthetic room prior to the  
procedure.  The Von-Frey hairs were shown to the subjects and applied to their 
abdominal wall so that they understood what they would feel like during testing.  
Then, subjects were asked to close their eyes to limit visual feedback during testing, 
and each dermatome from T8 to L1 on the left and the right were tested in turn.  The 
area of testing for each dermatome was at a point considered to be in the centre of the 
dermatome in the caudal-cranial direction and approximately 5 cm laterally from the 
midline.  The Von-Frey filaments with increasing thickness were applied to each area 
until the subject could feel the filament.  This method of testing is called the “Method 
of Limits” (Gruener & Dyck 1994; Keizer 2009).  Each Von-Frey filament was 
applied to the skin three times for approximately two seconds each with a variable 
interval of time between applications.  The detection threshold was defined as the 
logarithmic number on the filament that resulted in at least two out of three 
applications being detected by the subject.  
 
2.5.3  Surgical data 
The surgical procedures and estimated blood loss were recorded from the operation 
report at the end of each study protocol.  The duration of surgery, defined as the time 
from performing the TAP block to the time of extubation, was recorded.  
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2.5.4  Adverse effects 
Sedation 
The level of sedation of the patients was assessed at 30 and 60 minutes after 
extubation using the Ramsay Sedation Scale (Ramsay et al. 1974).  The Ramsay 
Sedation Scale is as follows: 
Table 2.2.  Explanation of Ramsay Sedation Scale 
Ramsay 
Sedation Score Description 
1 Patient is anxious and agitated or restless, or both 
2 Patient is co-operative, oriented, and tranquil 
3 Patient responds to commands only 
4 Patient exhibits brisk response to light glabellar tap or loud auditory stimulus 
5 Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus 
6 Patient exhibits no response 
 
Haemodynamic effects 
Any significant haemodynamic changes of the subjects that occurred during the 
course of the study protocol were obtained from their anaesthetic and observations 
charts.  The significant haemodynamic changes were defined as:  decrease in systolic 
blood pressure >30% from baseline systolic blood pressure and decrease in heart rate 
to less than 45 beats per minute.  Medications administered to treat haemodynamic 
changes (metaraminol and atropine) were also recorded.  
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Post operative nausea and vomiting 
The medication charts of the subjects were reviewed after the study protocol was 
completed and the administration of anti-emetic medications was recorded.  This was 
used as a surrogate marker for the incidence of post-operative nausea and vomiting.  
 
2.6  Laboratory methods 
Total plasma ropivacaine concentrations of the blood samples of the subjects were 
measured using a gas chromatograph mass spectrometer as described below. 
 
2.6.1  Chemicals 
Ropivacaine hydrochloride 1% (Naropin) and bupivacaine hydrochloride 0.5% 
(Marcain) were purchased from AstraZeneca, Sydney.  Methanol, sodium hydroxide, 
and diethyl ether were obtained from Merck Australia.  
 
2.6.2  Gas chromatograph mass spectrometry 
The blood samples were analysed using a gas chromatograph mass spectrometer 
(QP2010SE, Shimadzu Scientific Instruments, Rydalmere, Australia) with an 
autosampler (AOC-Zoi, Shimadzu).  A DB-5 chemical bonded silica capillary column 
(15m x 0.25mm I.D., film 0.25 µm, J&W Scientific, Polsom, CA, USA) was used.  
The column oven program was 120°C for 1 minute, followed by an increase to 230°C 
at a rate of 40°C/min and then maintained at a constant temperature for 3.8 min.  The 
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injector temperature was 300°C.  A split injection mode with a ratio of 30:1 was used.  
The carrier gas was helium and the column flow was 1 ml/min.  The interface 
temperature was 280°C, and the source temperature was 280°C.  The scan speed was 
1666 atomic mass units per second (amu/s) and mass range was 35-500 Dalton.  The 
peak area and height were integrated by GCMS solution data processing system. 
 
2.6.3  Quantification of ropivacaine 
Ropivacaine was identified using the GCMS by scanning to find electron ionization 
mass and gas chromatograph retention time.  The peak of the ropivacaine base was 
quantified using the selected ion monitoring (SIM) program of the GCMS.  The SIM 
revealed that ropivacaine had a mass-to-charge ratio (M/Z) of 126 and a retention 
time of 5.49 minutes (Figure 2.5).  These values were compared with the values of 
known compounds in the Shimadzu mass spectral library and they were found to be 
consistent with ropivacaine.  
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Figure 2.5.  Gas chromatogram of ropivacaine showing retention time and mass-to-charge ratio   
Bupivacaine was chosen as the internal standard because it is a similar amino amide 
local anaesthetic drug and has a similar structure as ropivacaine.  When it was 
scanned, its mass-to-charge ratio was 140 and its retention time was 5.92 minutes.  
(Figure 2.6)  
 
Ropivacaine 
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Figure 2.6.  Gas chromatogram of bupivacaine showing retention time and mass-to-charge ratio 
 
2.6.4  Preparation of standard solutions  
The standard solutions of ropivacaine (0.1 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 µg/ml, and 3 
µg/ml) were prepared by serial dilution of 1% ropivacaine hydrochloride with blank 
thawed human plasma (obtained from the blood bank at Royal Prince Alfred 
Hospital). 
The internal standard was prepared using serial dilutions of 0.5% bupivacaine 
hydrochloride with distilled water. 
Bupivacaine 
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Quality control (QC) solutions were also prepared by serial dilution of 1% 
ropivacaine hydrochloride with blank human plasma.  The QC concentrations used 
were 0.6 µg/ml and 2.5 µg/ml.  These two QCs were made for each run of samples 
performed by the GCMS to ensure that that the results obtained were accurate. 
 
2.6.5  Standard curve (calibration) 
A standard curve was produced using the standard solutions of known concentrations 
as described in 2.6.4.  The extraction of ropivacaine from the standard samples was 
performed in the same way as extraction of ropivacaine from the subjects’ samples as 
described in 2.6.6.  Figure 2.7 shows an example of a standard calibration curve.  For 
each run of the GCMS (which included the samples from two subjects), a set of 
standard concentrations were prepared and a standard curve was produced.  This 
curve was then used to determine the ropivacaine concentrations of the samples from 
the subjects. 
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Figure 2.7.  Example of a standard calibration curve from the Shimadzu GCMS 
 
2.6.6  Measurement of ropivacaine concentration 
Prior to measuring the plasma ropivacaine concentrations of the standard solutions 
and blood samples of the subjects, ropivacaine was extracted from the samples using 
a liquid-liquid extraction technique.  First, 40 µL of the internal standard, bupivacaine 
diluted to a concentration of 5 µg/ml was added to each labeled polypropylene test 
tube.  Plasma (500 µL) from each sample (or standard solution) was then added to the 
internal standard and the tubes were agitated.  Sodium hydroxide (8 M) 100 µL 
followed by 5 ml of diethyl ether was then added to each test tube, before they were 
mixed on a rotary mixer for 30 minutes and then centrifuged for 15 minutes at 4000 
rpm at 4°C.  The mixing and centrifugation processes separated the solutions into two 
distinct phases (upper and lower).  The upper phase of each solution was then 
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transferred into a second set of test tubes and these were dried under nitrogen at 40°C 
until all the liquid was evaporated (approximately 40 minutes).  The residue in each 
tube was then dissolved in 100 µL of methanol and 1 µl of this was injected into the 
GCMS.  
 
2.6.7  Validation of assay 
The ropivacaine assay was validated for precision and accuracy.  To determine intra-
day accuracy and precision, three sets of samples of five different ropivacaine 
concentrations (0.7 µg/ml, 1.2 µg/ml, 1.7 µg/ml, 2.2 µg/ml, and 2.7 µg/ml) were used.  
To determine inter-day accuracy and precision, samples with these concentrations 
were produced and analysed on three separate days.  All of the samples underwent the 
same extraction process as described in 2.6.6. 
 
Intra-day accuracy and precision 
Table 2.3 summarises the intra-day accuracy (expressed as percent error) and 
precision (expressed as coefficient of variation) of ropivacaine measurements for 
three separate days. 
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Table 2.3.  Intra-day accuracy and precision of ropivacaine measurements from three days 
Ropivacaine 
concentration                      
(µg/ml) 
 
0.7 
 
1.2 
 
1.7 
 
2.2 
 
2.7 
 DAY 1 
Mean 
concentration 
(µg/ml) 
 
0.75 
 
1.32 
 
1.90 
 
2.25 
 
2.89 
Percent error 
(%) 
 
 
7.3 
 
10.0 
 
12.0 
 
2.1 
 
7.0 
Coefficient of 
variation (%) 
 
8.3 
 
7.0 
 
9.5 
 
5.2 
 
12.9 
 DAY 2 
Mean 
concentration 
(µg/ml) 
 
0.69 
 
1.17 
 
1.70 
 
2.14 
 
2.66 
Percent error 
(%) 
 
 
2.0 
 
2.3 
 
0.1 
 
2.9 
 
1.6 
Coefficient of 
variation (%) 
 
2.2 
 
1.4 
 
2.5 
 
2.0 
 
2.9 
 DAY 3 
Mean 
concentration 
(µg/ml) 
.67 1.17 1.68 2.14 2.66 
Percent error 
(%) 
 
4.3 
 
2.2  1.1 2.7 1.4 
Coefficient of 
variation (%) 
 
4.2 3.1 1.2 1.1 1.2 
 
Inter-day accuracy and precision 
Table 2.4 summarises the inter-day accuracy (expressed as percent error) and 
precision (expressed as coefficient of variation) of ropivacaine measurements over 3 
days. 
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Table 2.4.  Inter-day accuracy and precision over three days 
 
 
Quality control 
On every occasion when subjects’ samples were processed by the GCMS (samples 
from two subjects were processed each run), QC samples were also included.  These 
samples had ropivacaine concentrations of 0.6 µg/ml and 2.5 µg/ml.  There were 40 
runs of the GCMS to analyse the 80 subject samples.  Table 2.5 summarises the mean 
values for the QC samples, the percent errors, and the coefficient of variations. 
Table 2.5.  Accuracy and precision of quality control samples 
 
 
Ropivacaine 
concentration 
(µg/ml) 0.7 1.2 1.7 2.2 2.7 
Mean 
concentration 
(µg/ml) 
0.70 1.22 1.76 2.18 2.74 
Percent error 
(%) 
 
0.3 1.8 3.6 1.1 1.3 
Coefficient of 
variation (%) 
 
7.3 7.3 8.1 3.8 8.1 
Ropivacaine concentration 
(µg/ml) 
 
0.6 
 
2.5 
Mean concentration 
(µg/ml) 
0.60 2.56 
Percent error (%) 
 
0.5 2.4 
Coefficient of variation (%) 
 
5.2 5.3 
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2.7  Statistical analyses 
2.7.1  Sample size estimation 
The primary aim of this study was to investigate the proposed mechanisms by which 
clonidine enhances the duration of local anaesthetic action.  Mazoit et al demonstrated 
that clonidine directly constricts blood vessels when administered into the epidural 
space (Mazoit et al. 1996).  This pharmacokinetic study was undertaken to clarify 
whether this vasoconstrictor effect would be an important factor in the prolongation 
of local anaesthetic by clonidine, using plasma ropivacaine levels as an indication of 
the degree of vasoconstriction.  There are no data evaluating the effects of clonidine 
on the plasma levels of local anaesthetic drugs when it is added to the local 
anaesthetic injectate for infiltration or regional anaesthesia.  Based on the hypothesis 
that clonidine causes local vasoconstriction, it was further hypothesized that clonidine 
causes local vasoconstriction similar to that of adrenaline and therefore decreases the 
absorption and thus the plasma concentration of the local anaesthetic drug.  Karmakar 
et al conducted a study evaluating the effect of adding adrenaline to ropivacaine in 
paravertebral blocks on arterial and venous plasma ropivacaine concentrations 
(Karmakar et al. 2005).  They reported a mean peak arterial plasma concentration of 
2.47 ± 0.5 µg/ml in the plain ropivacaine group compared with 1.85 ± 0.7 µg/ml in 
the ropivacaine with adrenaline group.  The peak venous levels were not reported.   
To determine if clonidine reduced local anaesthetic uptake, when compared to 
controls in a TAP block model not dissimilar to Karmakar’s paravertebral model, a 
sample calculation using these values with α=0.05 indicated that an estimated sample 
size of 15 subjects per group was required to provide a power of 0.80 to find a similar 
difference.  Based on the assumption that clonidine might cause less vasoconstriction 
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than adrenaline and thereby have a smaller effect size, the sample size was increased 
to include 20 subjects in each group. 
An adrenaline group consisting of 20 subjects was also included in the study.  
Because adrenaline is a known vasoconstrictor, it was considered that if a 
vasoconstrictor effect was observed in the clonidine group it would be useful to have 
an adrenaline group with which to compare the degree of vasoconstriction that 
occurred. 
A fourth group included 20 subjects who received subcutaneous (SC) clonidine in 
addition to ropivacaine TAP blocks.  This group was included to determine whether 
any vasoconstriction observed with clonidine was mediated by a peripheral or central 
mechanism.  If the clonidine group had lower plasma ropivacaine concentrations than 
the control group and the SC clonidine group had similar concentrations to the control 
group, it could be hypothesized that clonidine caused vasoconstriction directly rather 
than centrally following its absorption into the systemic circulation. 
 
2.7.2  Statistical methods 
Subject characteristics and outcome measures that were defined by categorical 
variables were reported as number and frequency (percentage), whereas those defined 
by numerical variables were reported as mean and standard deviation. 
In order to compare control and intervention groups, parametric demographic data, 
surgical data, and plasma ropivacaine concentration data were analysed using the 
Student’s T-test (two-sided, equal variances, unpaired), and non-parametric data were 
analysed using the Mann-Whitney U test.  The data on heat, cold, and mechanical 
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sensation were not normally distributed, and the observed proportions were compared 
using non-parametric x2 analysis and Fisher exact test.  Correlation analyses of subject 
body weight and plasma ropivacaine concentrations were performed using Pearson’s 
Product-Moment Correlation.  P<0.05 was considered significant. 
Statistical analyses were performed using IBM® SPSS® Statistics v20 (IBM 
Corporation) and GraphPad Prism Software version 6.0 (CA, USA). 
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CHAPTER 3:  RESULTS 
3.1  Recruitment 
Eighty subjects undergoing laparoscopic gynaecological surgery were recruited into 
the trial from June 2014 to November 2015.  All 80 subjects completed the entire 
study protocol. 
 
3.2  Baseline data 
The baseline demographic data, ASA score, estimated blood loss, and duration of 
surgery are summarized in table 3.1. 
The age and height of the subjects were well balanced, however the weight of the 
subjects in the clonidine and SC clonidine groups was significantly greater than that 
of the subjects in the control group (P=0.001 and P=0.017 respectively).  The BMI of 
subjects in the clonidine group was significantly greater than that of the subjects in 
the control group (P=0.007).   
There were no important differences between the study groups in terms of ASA 
scores, estimated blood loss, and duration of surgery. 
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Table 3.1.  Baseline data.  Data are means (SD).  *Significant difference from control group (P<0.05).   
**Significant difference from control group (P<0.01) 
Variables 
 
Study Group 
Control 
(n=20) 
 Clonidine 
 (n=20) 
 Adrenaline 
 (n=20) 
SC Clonidine 
(n=20) 
Age (years) 37.4 (6.5) 37.1 (8.2) 36.8 (10.5) 36.6 (6.8) 
Height (cm) 159.0 (13.2) 164.1 (7.2) 164.6 (6.7) 166.0 (8.8) 
Weight (kg) 60.3 (9.6) 77.0 (18.7)* 65.4 (11.2) 70.0 (14.4)* 
BMI (kg/m2) 23.2 (4.6) 28.0 (6.0)** 23.6 (3.8) 25.0 (5.4) 
ASA score 1.3 (0.5) 1.55 (0.5) 1.4 (0.5) 1.35 (0.5) 
Estimated 
blood loss (ml) 91.8 (113.4) 82.3 (95.2) 45.9 (36.6) 95.1 (155.7) 
Duration of 
surgery (min) 108.8 (56.7) 131.8 (40.8) 104.8 (46.2) 126.4 (92.0) 
 
All subjects underwent laparoscopic gynaecological surgery.  The surgical procedures 
are summarized in table 3.2.  Several of the subjects underwent more than one 
procedure. 
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Table 3.2.  Surgical procedures performed by study group.  Data are number (percentage of group) 
 Study Group 
Surgical Procedures 
Performed 
 
Control 
(n=20) 
Clonidine 
(n=20) 
Adrenaline 
(n=20) 
SC Clonidine 
(n=20) 
Excision of 
endometriosis 16 (80%) 8 (40%) 16 (80%) 14 (70%) 
Hysterectomy 3 (15%) 7 (35%) 3 (15%) 3 (15%) 
Ovarian cystectomy 3 (15%) 3 (15%)   
Salpingectomy or 
Salpingo-oopherectomy 3 (15%) 7 (35%) 5 (25%) 4 (20%) 
Reversal of tubal 
ligation    1 (5%) 
Myomectomy or 
polypectomy   1 (5%) 3 (15%) 
Hysteroscopy 9 (45%) 5 (25%) 5 (25%) 4 (20%) 
Insertion of IUD 2 (10%) 3 (15%) 2 (10%) 4 (20%) 
Cystoscopy 1 (5%) 6 (30%) 2 (10%) 1 (5%) 
Insertion of ureteric 
stent   1 (5%) 1 (5%) 
Bowel resection 1 (5%) 2 (10%) 1 (5%) 3 (15%) 
Ileostomy 1 (5%)    
 
In two subjects (one in the control group and one in the clonidine group) the 
laparoscopic procedures were converted to open procedures via Pfannenstiel incisions 
because of difficulties with surgical access provided by the laparoscopic approach. 
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3.3  Plasma ropivacaine concentrations 
3.3.1  Total plasma ropivacaine concentrations after TAP blocks 
The plasma ropivacaine concentrations over time of each of the subjects in the four 
study groups are shown in figure 3.1.  There were no significant differences between 
the plasma ropivacaine concentrations of the control group and the clonidine group at 
any of the timepoints (table 3.3 and figure 3.2).  The mean maximum ropivacaine 
concentration (Cmax) and mean time to peak ropivacaine concentration (Tmax) of the 
clonidine group did not differ from those of the control group (table 3.4). 
 
Figure 3.1. Plasma ropivacaine concentrations over time of each of the subjects in the (A) plain 
ropivacaine group; (B) ropivacaine with adrenaline group; (C) ropivacaine with clonidine group; 
and (D) ropivacaine and SC clonidine group.  
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Table 3.3. Group statistics for control and clonidine groups.  (Unit for mean is mcg/ml.) 
Group Statistics 
Time 
point 
Group N Mean SD Sig Mean 
difference 
95% CI of difference 
Lower Upper 10 min Control Clonidine 20 20 0.875 1.043 .3209 .3176 .105 -0.168 -0.372 0.037 20 min Control Clonidine 20 20 1.313 1.371 .4641 .4766 .699 -0.058 -0.359 0.243 30 min Control Clonidine 20 20 1.633 1.693 .5248 .5626 .733 -0.059 -0.407 0.289 40 min Control Clonidine 20 20 1.805 1.849 .6001 .5900 .819 -0.043 -0.424 0.338 50 min Control Clonidine 20 20 1.854 1.854 .5756 .5688 .999 0.000 -0.366 0.367 60 min Control Clonidine 20 20 1.795 1.829 .7138 .5054 .863 -0.034 -0.430 0.362 90 min Control Clonidine 20 20 1.579 1.665 .5360 .4939 .600 -0.086 -0.416 0.244 120 min Control Clonidine 20 20 1.390 1.460 .4628 .4671 .641 -0.069 -0.367 0.229 150 min Control Clonidine 20 20 1.221 1.326 .4416 .4880 .479 -0.105 -0.403 0.193 180 min Control Clonidine 20 20 1.116 1.204 .4408 .4868 .558 -0.088 -0.390 0.214 360 min Control Clonidine 20 20 0.782 0.916 .3693 .4722 .322 -0.135 -0.406 0.137 
Abbreviations: min, minute; N, number of patients; SD, standard deviation; sig, significance (2-tailed); CI, confidence interval
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Figure 3.2.  Plasma ropivacaine concentrations after TAP blocks in control and clonidine groups. 
 
 
Table 3.4.  Maximum ropivacaine concentration (Cmax) and time to peak concentration (Tmax) for 
each study group.  * P<0.01 compared to control group  
Group 
Cmax [Mean (SD)] 
(mcg/ml) 
Tmax – [Mean (SD)] 
(min) 
Control 1.99 (0.59) 51.0 (20.0) 
Clonidine 2.05 (0.55) 56.0 (29.8) 
Adrenaline 1.36 (0.37)* 103.5 (55.1)* 
SC Clonidine 2.13 (0.56) 43.5 (16.3) 
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The plasma ropivacaine concentrations of the subjects in the adrenaline group were 
significantly lower than in the control group at 10, 20, 30, 40, 50, 60, and 90-minute 
timepoints (P<0.003) (table 3.5 and figure 3.3).  The plasma/time profile of the 
ropivacaine concentration of the adrenaline group was different from that of the 
control group.  There was a plateau in the adrenaline group in contrast to a distinct 
peak in the control group.  The Cmax was 1.36 mcg/ml in the adrenaline group, and 
this was significantly less than in the control group (1.99 mcg/ml; P=0.000) (table 
3.4).  The Tmax was delayed in the adrenaline group at 103.5 min compared with 51.0 
min in the control group (P=0.001). 
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Table 3.5.  Group statistics for control and adrenaline groups.  (Unit for mean is mcg/ml.) 
Group Statistics 
Time 
point 
Group N Mean SD Sig Mean 
difference 
95% CI of difference 
Lower Upper 10 min Control Adrenaline 20 20 0.875 0.536 .3209 .2326 .000 0.339 0.160 0.519 20 min Control Adrenaline 20 20 1.313 0.731 .4641 .3193 .000 0.583 0.328 0.838 30 min Control Adrenaline 20 20 1.633 0.947 .5248 .3038 .000 0.687 0.406 0.967 40 min Control Adrenaline 20 20 1.805 1.153 .6001 .3571 .000 0.652 0.330 0.975 50 min Control Adrenaline 20 20 1.854 1.171 .5756 .3144 .000 0.684 0.387 0.980 60 min Control Adrenaline 20 20 1.795 1.190 .7138 .3491 .002 0.605 0.245 0.965 90 min Control Adrenaline 20 20 1.579 1.137 .5360 .3016 .003 0.442 0.163 0.720 120 min Control Adrenaline 20 20 1.390 1.193 .4628 .3759 .146 0.198 -0.719 0.468 150 min Control Adrenaline 20 20 1.221 1.138 .4416 .3611 .521 0.083 -0.176 0.341 180 min Control Adrenaline 20 20 1.116 1.174 .4408 .4028 .674 -0.058 -0.336 0.220 360 min Control Adrenaline 20 20 0.782 0.876 .3693 .3468 .412 -0.094 - 0.323 0.135 
Abbreviations: min, minute; N, number of patients; SD, standard deviation; sig, significance (2-tailed); CI, confidence interval
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Figure 3.3.  Plasma ropivacaine concentrations after TAP blocks in control and adrenaline groups. 
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There were also no differences between the plasma ropivacaine concentrations of the 
control group and the SC clonidine group (table 3.6 and figure 3.4).  Additionally, the 
Cmax and Tmax of the SC clonidine group did not differ from those of the control group. 
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 Table 3.6.  Group statistics for control and SC clonidine groups.  (Unit for mean is mcg/ml.) 
Group Statistics 
Time 
point 
Group N Mean SD Sig Mean 
difference 
95% CI of difference 
Lower Upper 10 min Control SC Clonidine 20 20 0.875 1.201 .3209 .5382 .025 -0.326 -0.610 -0.042 20 min Control SC Clonidine 20 20 1.313 1.463 .4641 .3900 .284 -0.150 -0.429 0.129 30 min Control SC Clonidine 20 20 1.633 1.835 .5248 .4780 .218 -0.202 -0.528 0.125 40 min Control SC Clonidine 20 20 1.805 1.926 .6001 .4500 .496 -0.120 -0.474 0.233 50 min Control SC Clonidine 20 20 1.854 1.975 .5756 .5843 .516 -0.120 -0.491 0.251 60 min Control SC Clonidine 20 20 1.795 1.883 .7138 .5294 .662 -0.088 -0.490 0.315 90 min Control SC Clonidine 20 20 1.579 1.662 .5360 .5440 .629 -0.083 -0.429 0.263 120 min Control SC Clonidine 20 20 1.390 1.446 .4628 .4892 .715 -0.055 -0.360 0.250 150 min Control SC Clonidine 20 20 1.221 1.358 .4416 .4538 .346 -0.137 -0.427 0.154 180 min Control SC Clonidine 20 20 1.116 1.179 .4408 .4549 .661 -0.064 -0.354 0.227 360 min Control SC Clonidine 20 20 0.782 0.883 .3693 .4334 .437 -0.101 -0.362 0.160 
Abbreviations: min, minute; N, number of patients; SD, standard deviation; sig, significance (2-tailed); CI, confidence interval
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Figure 3.4.  Plasma ropivacaine concentrations after TAP blocks in control and SC clonidine groups.  
 
3.3.2  Plasma ropivacaine concentrations and body weight 
Despite randomization, subjects in the clonidine and SC clonidine groups were found 
to weigh significantly more than subjects in the control group.  Because of this, data 
were analysed to determine if any correlation existed between body weight and 
plasma ropivacaine concentrations to establish whether or not body weight could be a 
confounding factor.  Within each study group a Pearson correlation test was 
performed to detect any correlations between subject body weight and plasma 
ropivacaine concentrations.  There was no correlation between weight and 
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ropivacaine concentrations in the control, adrenaline, or SC clonidine groups.  The 
only correlation found was in the clonidine group at the six-hour time point.  The 
Pearson Correlation was 0.552 (P=0.012). 
 
3.3.3  Potential for ropivacaine toxicity 
Seven subjects in the control group as well as eight subjects in the clonidine group 
and seven subjects in the SC clonidine group had total venous plasma ropivacaine 
concentrations greater than 2.2 mcg/ml at a minimum of one sampling time point 
during the study.  No subjects in the adrenaline group reached this level (P<0.004). 
No subjects reported symptoms consistent with local anaesthetic toxicity during the 
study.  
Table 3.7 demonstrates the number of subjects in each group with venous plasma 
ropivacaine concentrations greater than 2.2 mcg/ml at each timepoint.
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Table 3.7.  Number of subjects (percent of group) with plasma ropivacaine concentrations greater than 2.2 mcg/ml at each time point by study group. 
Study 
Group 
Time points (minutes) 
10 20 30 40 50 60 90 120 150 180 360 
Control   3 (15%) 5 (25%) 5 (25%) 3 (15%) 2 (10%) 1 (5%) 1 (5%)   
Clonidine  1 (5%) 2 (10%) 5 (25%) 6 (30%) 6 (30%) 4 (25%) 1 (5%) 2 (10%) 1 (5%) 1 (5%) 
Adrenaline            
SC Clonidine  1 (5%) 3 (15%) 6 (30%) 6 (30%) 4 (25%) 4 (25%) 1 (5%) 1 (5%) 1 (5%)  
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3.4  Measurements of sensory modalities 
Heat, cold, and mechanical sensation was tested bilaterally from dermatome T8 to L1 
at three and six hours after the TAP block was performed.  At the three-hour time 
point sensory assessments could not be performed in 29 subjects (seven in the control 
group, six in the adrenaline group, eleven in the clonidine group, and five in SC 
clonidine group).  The reasons for the inability to assess sensation included: remained 
under general anaesthetic (n=20), drowsiness (n=4), patient refusal due to pain (n=3), 
and patient refusal due to post operative nausea and vomiting (n=2).  At the six-hour 
time point, four subjects could not be assessed (one subject from each group).  These 
patients could not be assessed due to drowsiness. 
 
3.4.1  Heat sensation 
For statistical analysis, each dermatome on the left and right side of each subject was 
analysed separately.  When each dermatome was compared in terms of heat sensation 
there were only two significant differences: the control group had more heat 
insensitivity compared with the clonidine group at T11 at the three hour time point 
(P=0.015), and the control group had more heat insensitivity compared with the 
adrenaline group at T11 at 6 hours (P=0.011) (table 3.8). 
When the number of heat insensitive dermatomes at six hours from T10 to L1 in each 
group were combined and compared with the control group using Fisher’s exact test, 
the adrenaline group had significantly more heat sensitivity than the control group 
(P=0.026). 
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Table 3.8.  Number (percentage) of dermatomes in each group that were insensitive to heat.  * Indicates a significant difference from the control group. 
Study Group 
Dermatomes with Lack of Heat Sensation 
3 Hours after TAP Block 6 Hours after TAP Block 
T8 T9 T10 T11 T12 L1 T8 T9 T10 T11 T12 L1 
Control 0/26 (0%) 
0/26 
(0%) 
4/26 
(15.4%) 
20/26 
(76.9%) 
13/26 
(50%) 
2/26 
(7.7%) 
0/38 
(0%) 
0/38 
(0%) 
5/38 
(13.2%) 
26/38 
(68.4%) 
21/38 
(55.3%) 
5/38 
(13.2%) 
Clonidine 0/18 (0%) 
0/18 
(0%) 
2/18 
(11.1%) 
7/18* 
(38.9%) 
4/18 
(22.2%) 
3/18 
(16.7%) 
0/38 
(0%) 
0/38 
(0%) 
4/38 
(10.5%) 
19/38 
(50%) 
16/38 
(42.1%) 
5/38 
(13.2%) 
Adrenaline 0/26 (0%) 
0/28 
(0%) 
4/28 
(14.3%) 
16/28 
(57.1%) 
13/28 
(46.4%) 
5/28 
(17.9%) 
0/38 
(0%) 
0/38 
(0%) 
4/38 
(10.5%) 
14/38* 
(36.8%) 
15/38 
(39.5%) 
5/38 
(13.2%) 
SC Clonidine 0/30 (0%) 
2/30 
(6.7%) 
7/30 
(23.3%) 
23/30 
(76.7%) 
22/30 
(73.3%) 
3/30 
(10%) 
0/38 
(0%) 
2/38 
(5.3%) 
9/38 
(23.7%) 
27/38 
(71.1%) 
23/38 
(60.5%) 
7/38 
(18.4%) 
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3.4.2  Cold sensation 
The cold sensation data was analysed using a similar method as the heat sensation 
data described above.   
The only two significant differences in cold sensation were:  subjects in the SC 
clonidine group were less sensitive to cold than the control group at T12 at 3 hours 
(P=0.011), and subjects in clonidine group were more sensitive to cold than the 
control group at T11 at 6 hours (P=0.009) (table 3.9). 
When the number of dermatomes that were less sensitive to cold at six hours from 
T10 to L1 in each group were combined and compared to the control group, the 
clonidine group was significantly more sensitive to cold than the control group 
(P=0.027) when the Fisher exact test was applied.
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Table 3.9.  Number (percentage) of dermatomes in each group that were insensitive to cold.  * Indicates a significant difference from the control group. 
Study Group 
Dermatomes with Lack of Cold Sensation 
3 Hours after TAP Block 6 Hours after TAP Block 
T8 T9 T10 T11 T12 L1 T8 T9 T10 T11 T12 L1 
Control 0/26 (0%) 
0/26 
(0%) 
3/26 
(11.5%) 
18/26 
(69.2%) 
13/26 
(50%) 
4/26 
(15.4%) 
0/38 
(0%) 
0/38 
(0%) 
5/38 
(13.2%) 
29/38 
(76.3%) 
19/38 
(50%) 
5/38 
(13.2%) 
Clonidine 0/18 (0%) 
0/18 
(0%) 
4/18 
(22.2%) 
10/18 
(55.6%) 
5/18 
(27.8%) 
3/18 
(16.7%) 
0/38 
(0%) 
0/38 
(0%) 
3/38 
(7.9%) 
17/38* 
(44.7%) 
14/38 
(36.8%) 
5/38 
(13.2%) 
Adrenaline 0/26 (0%) 
2/28 
(7.1%) 
5/28 
(17.9%) 
20/28 
(71.4%) 
13/28 
(46.4%) 
5/28 
(17.9%) 
0/38 
(0%) 
0/38 
(0%) 
6/38 
(15.8%) 
23/38 
(60.5%) 
19/38 
(50%) 
5/38 
(13.2%) 
SC Clonidine 0/30 (0%) 
2/30 
(6.7%) 
7/30 
(23.3%) 
24/30 
(80%) 
25/30* 
(83.3%) 
5/30 
(16.7%) 
0/38 
(0%) 
2/38 
(5.3%) 
6/38 
(15.8%) 
26/38 
(68.4%) 
25/38 
(65.8%) 
6/38 
(15.8%) 
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3.4.3  Mechanical cutaneous sensation 
Mechanical cutaneous sensation was tested using Von-Frey Hairs.  Following the 
method described by Bollag et al (Bollag et al. 2012), the 180 g filament was used as 
the cut-off point between normal/minimally impaired sensation and abnormal 
sensation.  Each dermatome on the left and right side of each subject was analyzed 
separately for the statistical analysis.   
There were no significant differences in mechanical cutaneous sensation between 
groups at any dermatome (table 3.10).  When the number of dermatomes with 
abnormal mechanical cutaneous sensation at six hours from T10 to L1 in each group 
were combined and compared to the control group using Fisher’s exact test, no 
significant differences were found. 
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Table 3.10.  Number (percentage) of dermatomes in each group that were insensitive to 180g Von-Frey Hair. 
 
Study Group 
Dermatomes with Abnormal Light Touch Sensation 
3 Hours after TAP Block 6 Hours after TAP Block 
T8 T9 T10 T11 T12 L1 T8 T9 T10 T11 T12 L1 
Control 0/26 (0%) 
1/26 
(3.8%) 
3/26 
(11.5%) 
13/26 
(50%) 
8/26 
(30.8%) 
1/26 
(3.8%) 
0/38 
(0%) 
0/38 
(0%) 
3/38 
(7.9%) 
13/38 
(34.2%) 
10/38 
(26.3%) 
1/38 
(2.6%) 
Clonidine 0/18 (0%) 
0/18 
(0%) 
2/18 
(11.1%) 
7/18 
(38.9%) 
8/18 
(44.4%) 
1/18 
(5.6%) 
0/38 
(0%) 
0/38 
(0%) 
5/38 
(13.2%) 
14/38 
(36.8%) 
14/38 
(36.8%) 
7/38 
(18.4%) 
Adrenaline 0/26 (0%) 
2/28 
(7.1%) 
5/28 
(17.9%) 
8/28 
(28.6%) 
3/28 
(10.7%) 
1/28 
(3.6%) 
0/38 
(0%) 
0/38 
(0%) 
3/38 
(7.9%) 
12/38 
(31.6%) 
6/38 
(15.8%) 
0/38 
(0%) 
SC Clonidine 0/30 (0%) 
1/30 
(3.3%) 
4/30 
(13.3%) 
16/30 
(53.3%) 
11/30 
(36.7%) 
1/30 
(3.3%) 
0/38 
(0%) 
1/38 
(2.6%) 
3/38 
(7.9%) 
12/38 
(31.6%) 
9/38 
(23.7%) 
0/38 
(0%) 
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3.5 Adverse effects 
3.5.1  Haemodynamic effects 
The haemodynamic effects in the four groups are summarized in table 3.11.  There 
were no significant differences between the study groups and the control group in 
terms of haemodynamic effects. 
Table 3.11.  Number of subjects (percent) in each group that experienced haemodynamic side 
effects. 
Haemodynamic 
Parameter 
Study Group 
Control Clonidine Adrenaline SC Clonidine 
Decrease in  
SBP >30% 
5 (20%) 3 (15%) 1 (5%) 3 (15%) 
Metaraminol 
administered 
5 (20%) 3 (15%) 1 (5%) 2 (10%) 
Decrease in HR 
to <45 
1 (5%) 1 (5%) 0 1 (5%) 
Atropine 
administered 
0 1 (5%) 0 1 (5%) 
Abbreviations: SBP, systolic blood pressure; HR, heart rate 
 
3.5.2  Sedation 
The Ramsay Sedation Scale scores for all the subjects were 1, 2, or 3 when assessed 
at 30 and 60 minutes after extubation.  There were no significant differences between 
study groups in terms of subjects’ level of sedation (table 3.12). 
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Table 3.12.  Ramsay sedation scores 30 minutes and 60 minutes after extubation by group.  (Ramsay 
Sedation Scale:  1- Patient anxious or agitated or both; 2- Patient cooperative, oriented and tranquil; 
3- Patient responds to commands only) 
Study Group 
Ramsay Sedation Scale Scores 
 
Time: 30 minutes 
 
Time: 60 minutes 
1 
 
2 3 1 2 3 
Control 1  (5%) 
17  
(85%) 
2  
(10%) 
 20 
(100%) 
 
Clonidine  17  (85%) 
3  
(15%) 
1  
(5%) 
19  
(95%) 
 
Adrenaline  20 (100%) 
  20 
(100%) 
 
SC Clonidine  17 (85%) 
3  
(15%) 
 20 
(100%) 
 
 
 
3.5.3  Post operative nausea and vomiting 
Eight subjects in the control group required anti-emetic therapy for post-operative 
nausea and vomiting compared to nine subjects in the adrenaline group, ten subjects 
in the clonidine group, and 5 subjects in the SC clonidine group.  There were no 
statistically significant differences between groups. 
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CHAPTER 4:  DISCUSSION 
4.1  Main findings 
4.1.1  Plasma ropivacaine concentrations  
This study showed that there were no differences in the total plasma ropivacaine 
concentrations of subjects in the control group and subjects in the clonidine group at 
any time.  The mean maximum concentration (Cmax) and time to maximum 
concentration (Tmax) were also similar between the control group and clonidine group.  
The plasma ropivacaine concentrations of the adrenaline group were significantly 
lower than that of the control group at all time points from 10 to 90 minutes.  A 
defined peak in the concentration curve was observed in the control and clonidine 
groups, in contrast to a plateau in concentration from 40 to 180 minutes in the 
adrenaline group.  The Cmax of the adrenaline group was significantly lower (1.36 ± 
0.373 mcg/ml) than that of the control group (1.99 ± 0.585 mcg/ml) (P<0.001), and 
the Tmax was significantly longer in the adrenaline group (103.5 ± 55.09 minutes) 
compared with the control group (51.0 ± 19.97 minutes) (P<0.001).  There were no 
differences observed between the plasma ropivacaine concentrations, Cmax, or Tmax of 
the control group and the subcutaneous clonidine group. 
Clonidine prolongs the duration of local anaesthetic action, and as a result improves 
the quality of post-operative analgesia (Eledjam et al. 1991; Singelyn et al. 1992; 
Saied et al. 2000; Erlacher et al. 2001; Iskandar et al. 2001; Casati et al. 2001).  The 
exact mechanism of this prolongation is not known but several theories have been 
postulated.  Mazoit et al and Kopacz et al concluded that clonidine at concentrations 
of 15 and 10 mcg/ml respectively caused local vasoconstriction and limited the 
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washout of local anaesthetic, indicating a pharmacokinetic mechanism (Mazoit et al. 
1996; Kopacz & Bernards 2001).  However, there is also substantial evidence that the 
local anaesthetic prolongation associated with clonidine is mediated by a 
pharmacodynamic mechanism involving the current, Ih (Parkis & Berger 1997; Yagi 
& Sumino 1998; Kroin et al. 2004).  The aim of this trial was to seek further evidence 
that the proposed pharmacokinetic mechanism contributes to the local anaesthetic 
prolongation observed with clonidine. 
The results of this study showed that adrenaline, but not clonidine (in a concentration 
of 1.35 mcg/ml), slowed the uptake of ropivacaine into the systemic circulation.  This 
is in accordance with the findings of Gaumann et al who demonstrated that 3.75 
mcg/ml of clonidine added to brachial plexus blocks did not cause vasoconstriction 
(Gaumann et al. 1992).  However, higher concentrations of clonidine added to local 
anaesthetic have been shown to cause local vasoconstriction (Kopacz & Bernards 
2001; Mazoit et al. 1996), and therefore the vasoactive properties of clonidine may be 
concentration-dependent. 
The reduction in Cmax and longer Tmax observed with adrenaline in this study is in 
agreement with the findings of Kitayama et al who found that adding adrenaline to a 
TAP block injectate of ropovicaine and lignocaine caused vasoconstriction (Kitayama 
et al. 2014).  The doses of ropivacaine used in the Kitayama study differed from that 
used in this study, making a direct comparison of results difficult.  However, in both 
studies the Cmax of the adrenaline groups is approximately 65% of the Cmax of the 
control groups, and the Tmax of the adrenaline groups is approximately twice the Tmax 
of the control groups.  The decreased Cmax and longer Tmax found in our study is also 
in accordance with a similar study performed by Loadsman et al which utilized the 
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same study protocol in terms of local anaesthetic and adrenaline doses (Loadsman et 
al. 2013).  
Despite using randomisation in this study, the mean body weight of the subjects in the 
clonidine group and the SC clonidine group was significantly greater than that of the 
control group.  This study used a volume (and therefore amount) of local anaesthetic 
based on subject body weight and consequently the difference in mean weight 
between groups could represent a confounding factor.  In order to determine if this 
was a confounding factor, each study group was tested for correlation between weight 
and plasma ropivacaine concentrations at all time points.  The rationale for this testing 
was that if strong correlations between weight and plasma ropivacaine concentrations 
were demonstrated, this would indicate that subject body weight was likely a 
confounding factor in this study.  However, only a single correlation was found in the 
clonidine group and consisted of a correlation between subject body weight and 
plasma ropivacaine concentrations at the six-hour time point.  The finding of a single 
correlation at a late time point in a single group indicates that subject weight was not 
a confounding factor in determining plasma ropivacaine concentrations. 
This study demonstrated that clonidine, at a concentration of 1.35 mcg/ml did not 
prolong the duration of action of ropivacaine by causing vasoconstriction.  The 
absence of any demonstrated pharmacokinetic mechanism of action of clonidine, at 
this lower concentration, indicates that clonidine more likely increases the duration of 
local anaesthetic action by a pharmacodynamic mechanism such as those involving 
the hyperpolarization-activated cation current, Ih (Dalle et al. 2014; Kroin et al. 2004; 
Yagi & Sumino 1998). 
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4.1.2  Sensation 
When sensation to heat and cold of the subjects at each abdominal dermatome were 
compared between groups, there were very few significant differences between the 
control group and the other study groups at three and six hours.  No significant 
differences in mechanical sensation between the control group and other study groups 
were observed. 
However when dermatomes from T10 to L1 were considered together, two significant 
differences were found:  the plain ropivacaine (control) group was more insensitive to 
heat than the adrenaline group at six hours, and the control group was more 
insensitive to cold than the clonidine group at six hours.    
The finding that the adrenaline group was no different to the control group in terms of 
cold sensation and mechanical sensation and in fact had less sensory block to heat 
than the control group was unexpected.  The plasma ropivacaine concentrations of the 
adrenaline group were significantly lower than the control group, which likely 
indicates that the ropivacaine remained in the TAP plane and surrounding tissue for a 
longer period, and therefore would be expected to cause a stronger and longer lasting 
sensory block.  These results are inconsistent with Liu et al who found that adrenaline 
caused dose-dependent prolongation of lignocaine and bupivacaine anaesthesia, 
which correlated with the magnitude of vasoconstriction produced (Liu et al. 1995).  
However, our findings are consistent with those of Schoenmakers et al who found that 
adding adrenaline to ropivacaine in popliteal nerve blocks did not extend the duration 
of postoperative analgesia (Schoenmakers et al. 2015).   
The finding that the control group was more insensitive to cold than the clonidine 
group was also unexpected.  The fact that clonidine and adrenaline did not prolong 
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sensory block in this study could be due to a lack of power for this endpoint.  The 
study was powered to detect a difference in plasma ropivacaine levels, but the sample 
size was likely insufficient to detect a small but clinically relevant difference in 
sensation.  Other studies investigating the role of clonidine in prolonging the action of 
local anaesthetics have been powered to detect differences in pain scores, quality of 
analgesia, or the time to return of sensation with sample sizes of 20 to 25 subjects per 
group (Erlacher et al. 2000; Saied et al. 2000; Eledjam et al. 1991).  
 
4.1.3  Adverse effects 
There was no difference in the incidence of hypotension and bradycardia between 
groups in this study.  This is consistent with previous studies where a similar dose of 
150 mcg of clonidine was used (Singelyn et al. 1992; Eledjam et al. 1991; Erlacher et 
al. 2001; Saied et al. 2000; Duma 2004).  However, in the meta-analysis on clonidine 
as an adjuvant to peripheral nerve blocks by Pöpping et al, a significant difference in 
haemodynamic adverse effects was reported. There was significant heterogeneity in 
the doses of clonidine used and the definitions of hypotension and bradycardia used in 
the individual studies that contributed to this meta-analysis, which could have 
explained the differences in their findings.  
This study showed that a dose of 150 mcg of clonidine added to local anaesthetic for 
peripheral nerve blocks was a safe dose.  This is supported by Eledjam et al, Singelyn 
et al, Erlacher et al, El Saied et al, and Duma et al (Eledjam et al. 1991; Singelyn et al. 
1992; Erlacher et al. 2001; Saied et al. 2000; Duma 2004).  A trial with a larger 
sample size is required to provide more robust data on the safety of adding clonidine 
to local anaesthetic. 
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4.1.4  Ropivacaine toxicity after tap blocks 
Ropivacaine is known to cause central nervous system and cardiovascular toxicity, 
although there is limited evidence regarding the plasma concentration at which 
toxicity occurs.  The most specific study addressing this issue was performed by 
Knudsen et al who investigated the maximum tolerated dose and plasma 
concentration of ropivacaine and bupivacaine when administered as an IV infusion to 
healthy volunteers (Knudsen et al. 1997).  They found that the maximum tolerated 
total and free arterial plasma concentrations were 4.3 ± 0.6 mcg/ml and 0.56 ± 0.14 
mcg/ml respectively.  Venous blood samples were collected simultaneously and the 
corresponding total and free venous plasma concentrations were 2.2 ± 0.8 mcg/ml and 
0.15 ± 0.08 mcg/ml respectively. 
In the present study, twenty-two patients (27.5%) (seven in the control group, eight in 
the clonidine group, and seven in the SC clonidine group) experienced at least one 
total venous plasma ropivacaine concentration greater than 2.2 mcg/ml. However, no 
patients experienced symptoms or demonstrated signs of local anaesthetic toxicity. No 
patients in the adrenaline group had a total plasma ropivacaine concentration above 
the toxic threshold. 
The finding that a significant number of patients had a plasma concentration above 
the previously defined toxic threshold in the absence of toxic symptomatology is 
consistent with other studies (Brydone et al. 2015; Griffiths et al. 2010; Loadsman et 
al. 2013).  
There are some important limitations to consider about our findings.  Arterial blood 
sampling was not performed in the present study and therefore the arterial plasma 
concentrations which drive any systemic effects, should they exist, were not 
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measured.  The focus of the present study was not to investigate the toxicity of 
ropivacaine and, as a consequence, free venous plasma ropivacaine concentrations 
were also not measured.  Some studies have demonstrated that toxic total plasma 
ropivacaine concentrations are not necessarily associated with toxic free plasma levels 
of ropivacaine (Brydone et al. 2015; Loadsman et al. 2013).  Furthermore, for some 
patients, potentially toxic concentrations of ropivacaine occurred only when the 
patients were still under general anesthesia when they were unable to experience 
symptoms.  Additionally, some non-specific symptoms such as drowsiness or nausea 
in the post-operative period may not have been attributed to local anaesthetic toxicity, 
but to other common causes.  
 
4.2  Strengths of this study 
A single blinded investigator (the author) performed all of the TAP blocks in this trial 
to avoid introducing any difference in technique as a confounding factor.  This same 
investigator performed all blood sampling and processing and sensory testing in order 
to ensure standardization.  Similarly, only this investigator collected the data.  The 
investigator assisted in the anaesthetic management of the enrolled patients but the 
overall responsibility for patient management was that of the consultant anaesthetist.  
 
4.3  Limitations 
Despite randomization, the groups were not well balanced in terms of the body weight 
of the subjects.  This was of concern because the ropivacaine doses were based on the 
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actual body weight of subjects.  Using a stratified randomization technique whereby 
groups could have been balanced in terms of the body weight of subjects could have 
prevented this imbalance from occurring.    
Although the subjects in this study underwent elective laparoscopic gynaecological 
surgery, there was substantial variability in the surgery performed and the estimated 
blood loss.  This could have been a confounding factor in the study.  However, in 
order to recruit a sufficient number of patients to complete the trial in a timely 
fashion, the decision was made not to further restrict the patient population. 
Plasma ropivacaine concentrations were measured in venous rather than arterial 
plasma.  Venous plasma concentrations may not be sufficiently sensitive to detect 
small differences in Cmax and Tmax because unlike arterial concentrations, they can be 
affected by venomotor tone, perfusion, and the characteristics of the preceding tissue 
bed (Mather, L.E. & Tucker, G.T. 2009).  However,  in this study statistically 
significant differences were detected between the Cmax and Tmax of the plain 
ropivacaine group and the ropivacaine with adrenaline group.  It therefore is unlikely 
that if clonidine added to ropivacaine caused a similar degree of vasoconstriction to 
that of adrenaline with ropivacaine that this would not have been detected.  Although 
the measurement of arterial instead of venous plasma ropivacaine concentrations in 
this study would have been preferable, due to the fact that the recruited patients were 
undergoing minimally invasive laparoscopic surgery it was felt that the insertion of an 
arterial catheter for the sole purpose of research was overly invasive and would likely 
result in more patients refusing to participate.   
Plasma ropivacaine levels were compared at serial time points in this study which is a 
relatively insensitive method of assessing differences between groups compared to 
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using complex pharmacokinetic modelling.  In order to overcome this limitation, the 
maximum concentration (Cmax) and time to maximum concentration (Tmax) were 
calculated for each group and these parameters were also compared between groups. 
The sample size calculation for this trial was based on detecting a difference in 
plasma ropivacaine concentrations between the subjects in the control and clonidine 
groups.  An estimation of effect size was made from the study by Karmakar et al on 
ropivacaine with and without adrenaline in paravertebral blocks (Karmakar et al. 
2005).  However, this sample size of twenty patients per group was almost certainly 
insufficient to detect a clinically significant difference in the abdominal wall sensation 
of subjects.  
 
4.4  Suggestions for further research 
This study provides further evidence that the prolongation effect of local anaesthetic 
by the addition of clonidine, at the lower concentration of 1.35 mcg/ml is not 
mediated by a pharmacokinetic mechanism.  Further studies are required to elucidate 
the mechanism of action of clonidine when added to local anaesthetic.  These studies 
should focus on the potential pharmacodynamic mechanisms, particularly the 
involvement of alpha-2 adrenoceptors and the current Ih. 
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CHAPTER 5:  CONCLUSION 
Peripheral nerve and plexus blocks are frequently used in anaesthesia as a component 
of multimodal analgesia to manage post-operative pain.  Several drugs, including 
clonidine, have been added to local anaesthetics for regional nerve blocks with the 
aim of prolonging the duration of action of anaesthesia and analgesia (Brummett & 
Williams 2011).  Clonidine has been shown to prolong the duration of local 
anaesthetics in several trials (Eledjam et al. 1991; Iohom et al. 2005; Adnan et al. 
2005; Casati et al. 2001), however its mechanism of action is unclear.  It has been 
suggested that the effect of clonidine is mediated by a pharmacokinetic mechanism 
whereby it causes vasoconstriction leading to a slower washout of local anaesthetic 
from the area of deposition (Mazoit et al. 1996; Kopacz & Bernards 2001).  However, 
some animal studies have demonstrated a pharmacodynamic mechanism of clonidine 
involving the current, Ih (Dalle et al. 2014; Kroin et al. 2004). 
This study tested the hypothesis that adding clonidine in a concentration of 1.35 
mcg/ml to local anaesthetic causes vasoconstriction.  The lack of difference in total 
plasma ropivacaine concentrations, Cmax, and Tmax between subjects in the control 
group and the clonidine group demonstrated that clonidine does not cause 
vasoconstriction at this low concentration.  It is therefore likely that the prolongation 
of anaesthesia and analgesia observed clinically when clonidine is added to local 
anaesthetic is mediated by a pharmacodynamic mechanism. 
Several subjects in the control, clonidine, and SC clonidine groups had total plasma 
ropivacaine concentrations that exceeded the previously described maximum tolerated 
concentration at a minimum of one time point during the study.  It is difficult to 
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appreciate the importance of this finding in the absence of free plasma ropivacaine 
concentrations and without any signs or symptoms of local anaesthetic toxicity in the 
study subjects. 
No differences in abdominal wall sensation at three and six hours were observed 
between the four study groups.  This may have been due to a lack of power to detect a 
difference as the sample size calculation for this study was based on detecting a 
difference in plasma ropivacaine concentrations rather than sensation. 
This study does not support a pharmacokinetic mechanism of action of clonidine 
when added to local anaesthetic.  Further research should concentrate on potential 
pharmacodynamic mechanisms mediating the prolongation effect observed when 
clonidine is added to local anaesthetic. 
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·  Dr Jennifer Crawford, Department of Anaesthetics 
·  A/Prof John Loadsman, Department of Anaesthetics 
 
 
Study Procedures 
 
If you agree to participate in this study, you will be asked to sign the Participant 
Consent Form.  You will then undergo your surgery in the normal way. 
The nerve blocks, including the use of local anaesthetic, are routinely performed for 
patients having this type of surgery. For the study, the local anaesthetic solution will 
either be plain local anaesthetic or local anaesthetic with an additive drug 
(adrenaline and clonidine) added.  You may also receive an injection of clonidine 
under the skin after you are asleep.  What you receive will be determined randomly 
(like flipping a coin) and neither you nor the researcher collecting data will know 
which you receive. This is to keep any of us from inadvertently/ unconsciously 
affecting the results of the study.   
 
Blood samples will then be collected from you from a separate intravenous cannula, 
to avoid multiple punctures, for the 12 hours after the nerve blocks are performed.   
 
Once you are awake from your operation, we will also ask you to take part in 
intermittent non-painful tests of sensation of your abdomen.  This involves testing 
your ability to feel warm, cold, and light touch sensation on the skin of your 
abdomen, so that we can determine how well and for how long the nerve blocks 
have worked.   
 
In addition to the blood levels and results of sensory tests above, data such as your 
age, weight, and height, how much pain relief medication you required after your 
operation and whether or not you experienced any blood pressure changes, 
sedation, or other side effects will be recorded from your medical record. 
 
 
Risks 
 
All medical procedures - whether for diagnosis or treatment, routine or experimental 
– involve some risk of injury.  In addition, there may be risks associated with this 
study that are presently unknown and unforeseeable.  In spite of all precautions, you 
might develop medical complications from participating in this study. 
 
The risks of participating in this study are: 
 
1. Risks of the ultrasound-guided transversus abdominis plane block (which forms part 
of your anaesthetic care whether or not you choose to participate in the study) will be 
discussed with you by your anaesthetist, and will not be affected by your participation in the 
study.  
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2. Risks of additives to local anaesthetics:  
 
·  Adrenaline:   
o increased pulse rate and blood pressure (minor, easily treatable) 
o palpitations (rare) 
 
·  Clonidine:   
o increased or decreased blood pressure, decreased pulse rate 
(minor, easily treatable) 
o drowsiness post-operatively (minor, resolves within hours) 
o allergy (rare, clonidine used commonly in anaesthetics) 
 
 
3. Risk associated with blood sampling 
 
·  Blood collection normally involves some discomfort at the site from which the 
blood is taken. There is also a risk of some minor bruising at the site, which 
may last one to two days. We will minimise these risks of taking several 
samples by using your intravenous cannula (a second cannula will be inserted 
for this purpose after you are “asleep”) to obtain them all if possible. Most of 
the samples will be obtained while you are anaesthetised. 
 
It is important that women participating in this study are not pregnant.  If you are a 
woman of child-bearing potential and there is any possibility that you are pregnant, 
the researchers will perform a pregnancy (urine) test before you start in the study. 
 
 
Benefits 
 
While we intend that this research study furthers medical knowledge and may 
improve our provision of pain relief after surgery in the future, it may not be of direct 
benefit to you. 
 
 
Compensation for injuries or complications 
 
If you suffer any injuries or complications as a result of this study, you should contact 
the study doctor as soon as possible, who will assist you in arranging appropriate 
medical treatment. If you are eligible for Medicare, you can receive any medical 
treatment required to treat the injury or complication, free of charge, as a public 
patient in any Australian public hospital.   
 
In addition, you may have a right to take legal action to obtain compensation for any 
injuries or complications resulting from the study.  Compensation may be available if 
your injury or complication is sufficiently serious and is caused by unsafe drugs or 
equipment, or by the negligence of one of the parties involved in the study (for 
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example, the researcher, the hospital, or the treating doctor).  You do not give up 
any legal rights to compensation by participating in this study.  
 
 
Costs 
 
Participation in this study will not cost you anything, nor will you be paid. 
 
Voluntary Participation 
 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If 
you do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not affect your medical 
treatment or your relationship with the staff who are caring for you.   
 
 
Confidentiality 
 
All the information collected from you for the study will be treated confidentially, and 
only the researchers named above will have access to it. The study results may be 
presented at a conference or in a scientific publication, but individual participants will 
not be identifiable in such a presentation. 
 
 
Further Information 
 
When you have read this information, Dr Jennifer Crawford will discuss it with you 
further and answer any questions you may have.  If you would like to know more at 
any stage, please feel free to contact her on 02 9515 8564. 
 
This information sheet is for you to keep. 
 
 
Ethics Approval and Complaints 
 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the 
Sydney Local Health District.  Any person with concerns or complaints about the 
conduct of this study should contact the Executive Officer on 02 9515 6766 and quote 
protocol number X14-0011. 
 
 117 
APPENDIX II 
 
    
 
Ropivacaine levels and sensation after TAP blocks with and without additives  
Royal Prince Alfred Hospital, Participant Consent Form, Version 2, 25/02/2014 Page 1 of 1 
Department of Anaesthetics 
Royal Prince Alfred Hospital 
Missenden Rd  
Camperdown NSW 2050 
AUSTRALIA 
Tel: 61 2 9515 8564   Fax: 61 2 95192455 
 
Plasma ropivacaine concentrations and duration of sensory block after ultrasound-guided 
transversus abdominis plane block, with and without additives (adrenaline and clonidine), 
for gynaecological surgery 
 
 
 
PARTICIPANT CONSENT FORM 
 
 
I, .................. .................................................................................................................... [name]  
 
of 
 
............................................................................................................................. .…….[address]  
 
have read and understood the Information for Participants on the above named research study 
 
and have discussed the study with .............................................................................................. 
 
I have been made aware of the procedures involved in the study, including any known or expected 
inconvenience, risk, discomfort or potential side effect and of their implications as far as they are 
currently known by the researchers. 
 
I understand that my participation in this study will allow the researchers and others, as described 
in the Information for Participants, to have access to my medical record, and I agree to this. 
 
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
 
NAME:    ...........................................................................................................  
 
 
SIGNATURE:   ...........................................................................................................  
 
 
DATE:    ...........................................................................................................  
 
 
NAME OF WITNESS: ..................................................................................................  
 
 
SIGNATURE OF WITNESS: ..............................................................................................  
